0001610820 2025-08-01 2026-04-30 0001610820 BCTX:CommonSharesNoParValueMember 2025-08-01 2026-04-30 0001610820 BCTX:WarrantsToPurchaseCommonSharesNoParValueMember 2025-08-01 2026-04-30 0001610820 BCTX:WarrantsToPurchaseCommonSharesNoParValueOneMember 2025-08-01 2026-04-30 0001610820 BCTX:WarrantsToPurchaseCommonSharesNoParValueTwoMember 2025-08-01 2026-04-30 0001610820 2026-06-09 0001610820 2026-04-30 0001610820 2025-07-31 0001610820 2024-08-01 2025-07-31 0001610820 2026-02-01 2026-04-30 0001610820 2025-02-01 2025-04-30 0001610820 2024-08-01 2025-04-30 0001610820 us-gaap:CommonStockMember 2026-01-31 0001610820 us-gaap:AdditionalPaidInCapitalMember 2026-01-31 0001610820 us-gaap:WarrantMember 2026-01-31 0001610820 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-31 0001610820 us-gaap:RetainedEarningsMember 2026-01-31 0001610820 us-gaap:NoncontrollingInterestMember 2026-01-31 0001610820 2026-01-31 0001610820 us-gaap:CommonStockMember 2025-07-31 0001610820 us-gaap:AdditionalPaidInCapitalMember 2025-07-31 0001610820 us-gaap:WarrantMember 2025-07-31 0001610820 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-31 0001610820 us-gaap:RetainedEarningsMember 2025-07-31 0001610820 us-gaap:NoncontrollingInterestMember 2025-07-31 0001610820 us-gaap:CommonStockMember 2025-01-31 0001610820 us-gaap:AdditionalPaidInCapitalMember 2025-01-31 0001610820 us-gaap:WarrantMember 2025-01-31 0001610820 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-31 0001610820 us-gaap:RetainedEarningsMember 2025-01-31 0001610820 us-gaap:NoncontrollingInterestMember 2025-01-31 0001610820 2025-01-31 0001610820 us-gaap:CommonStockMember 2024-07-31 0001610820 us-gaap:AdditionalPaidInCapitalMember 2024-07-31 0001610820 us-gaap:WarrantMember 2024-07-31 0001610820 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-31 0001610820 us-gaap:RetainedEarningsMember 2024-07-31 0001610820 us-gaap:NoncontrollingInterestMember 2024-07-31 0001610820 2024-07-31 0001610820 us-gaap:CommonStockMember 2026-02-01 2026-04-30 0001610820 us-gaap:AdditionalPaidInCapitalMember 2026-02-01 2026-04-30 0001610820 us-gaap:WarrantMember 2026-02-01 2026-04-30 0001610820 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-02-01 2026-04-30 0001610820 us-gaap:RetainedEarningsMember 2026-02-01 2026-04-30 0001610820 us-gaap:NoncontrollingInterestMember 2026-02-01 2026-04-30 0001610820 us-gaap:CommonStockMember 2025-08-01 2026-04-30 0001610820 us-gaap:AdditionalPaidInCapitalMember 2025-08-01 2026-04-30 0001610820 us-gaap:WarrantMember 2025-08-01 2026-04-30 0001610820 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-08-01 2026-04-30 0001610820 us-gaap:RetainedEarningsMember 2025-08-01 2026-04-30 0001610820 us-gaap:NoncontrollingInterestMember 2025-08-01 2026-04-30 0001610820 us-gaap:CommonStockMember 2025-02-01 2025-04-30 0001610820 us-gaap:AdditionalPaidInCapitalMember 2025-02-01 2025-04-30 0001610820 us-gaap:WarrantMember 2025-02-01 2025-04-30 0001610820 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-02-01 2025-04-30 0001610820 us-gaap:RetainedEarningsMember 2025-02-01 2025-04-30 0001610820 us-gaap:NoncontrollingInterestMember 2025-02-01 2025-04-30 0001610820 us-gaap:CommonStockMember 2024-08-01 2025-04-30 0001610820 us-gaap:AdditionalPaidInCapitalMember 2024-08-01 2025-04-30 0001610820 us-gaap:WarrantMember 2024-08-01 2025-04-30 0001610820 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-08-01 2025-04-30 0001610820 us-gaap:RetainedEarningsMember 2024-08-01 2025-04-30 0001610820 us-gaap:NoncontrollingInterestMember 2024-08-01 2025-04-30 0001610820 us-gaap:CommonStockMember 2026-04-30 0001610820 us-gaap:AdditionalPaidInCapitalMember 2026-04-30 0001610820 us-gaap:WarrantMember 2026-04-30 0001610820 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-30 0001610820 us-gaap:RetainedEarningsMember 2026-04-30 0001610820 us-gaap:NoncontrollingInterestMember 2026-04-30 0001610820 us-gaap:CommonStockMember 2025-04-30 0001610820 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0001610820 us-gaap:WarrantMember 2025-04-30 0001610820 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-30 0001610820 us-gaap:RetainedEarningsMember 2025-04-30 0001610820 us-gaap:NoncontrollingInterestMember 2025-04-30 0001610820 2025-04-30 0001610820 2026-01-01 2026-01-31 0001610820 BCTX:BriaProTherapeuticsCorpMember 2026-02-18 2026-02-18 0001610820 BCTX:BriaCellTherapeuticsMember 2026-02-18 2026-02-18 0001610820 us-gaap:CommonStockMember 2026-02-18 2026-02-18 0001610820 BCTX:BriaProTherapeuticsCorpMember 2026-02-18 0001610820 BCTX:BCTherapeuticsMember 2026-04-30 0001610820 BCTX:SharePurchaseAgreementMember BCTX:BCTherapeuticsMember 2021-12-21 2021-12-21 0001610820 BCTX:SharePurchaseAgreementMember BCTX:BCTherapeuticsMember 2021-12-21 0001610820 BCTX:BCTherapeuticsMember BCTX:SharePurchaseAgreementMember 2021-12-21 0001610820 BCTX:TwoOptionsMember BCTX:SharePurchaseAgreementMember BCTX:BCTherapeuticsMember 2021-12-21 2021-12-21 0001610820 BCTX:TwoOptionsMember BCTX:SharePurchaseAgreementMember BCTX:BCTherapeuticsMember 2021-12-21 0001610820 srt:MinimumMember BCTX:SharePurchaseAgreementMember BCTX:BCTherapeuticsMember 2021-12-21 2021-12-21 0001610820 srt:MaximumMember BCTX:SharePurchaseAgreementMember BCTX:BCTherapeuticsMember 2021-12-21 2021-12-21 0001610820 BCTX:JuneTwoThousandTwentySevenMember BCTX:SharePurchaseAgreementMember BCTX:BCTherapeuticsMember 2025-08-01 2026-04-30 0001610820 BCTX:JuneTwoThousandTwentySevenMember BCTX:SharePurchaseAgreementMember BCTX:BCTherapeuticsMember 2026-04-30 0001610820 BCTX:SharePurchaseAgreementMember BCTX:BCTherapeuticsMember 2026-04-30 0001610820 BCTX:SharePurchaseAgreementMember BCTX:BCTherapeuticsMember 2026-04-30 2026-04-30 0001610820 BCTX:BCTherapeuticsMember 2025-08-01 2026-04-30 0001610820 BCTX:BCTherapeuticsMember 2026-04-30 0001610820 BCTX:BCTherapeuticsMember 2024-07-31 0001610820 BCTX:BCTherapeuticsMember 2024-08-01 2025-07-31 0001610820 BCTX:BCTherapeuticsMember 2025-07-31 0001610820 BCTX:BCTherapeuticsMember 2025-07-31 0001610820 srt:MaximumMember BCTX:AmalgamationAgreementMember 2026-04-30 0001610820 BCTX:AmalgamationAgreementMember 2026-04-30 0001610820 BCTX:AmalgamationAgreementMember BCTX:BriaCellTherapeuticsMember 2026-04-30 0001610820 BCTX:AmalgamationAgreementMember BCTX:BriaProTherapeuticsCorpMember 2026-04-30 0001610820 BCTX:OfficeAndLabSpaceMember 2025-08-01 2026-04-30 0001610820 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2026-04-30 0001610820 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2026-04-30 0001610820 us-gaap:CashAndCashEquivalentsMember 2026-04-30 0001610820 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2025-07-31 0001610820 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2025-07-31 0001610820 us-gaap:CashAndCashEquivalentsMember 2025-07-31 0001610820 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-04-30 0001610820 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-04-30 0001610820 us-gaap:ShortTermInvestmentsMember 2026-04-30 0001610820 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-07-31 0001610820 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-07-31 0001610820 us-gaap:ShortTermInvestmentsMember 2025-07-31 0001610820 us-gaap:FairValueInputsLevel1Member 2026-04-30 0001610820 us-gaap:FairValueInputsLevel2Member 2026-04-30 0001610820 us-gaap:FairValueInputsLevel1Member 2025-07-31 0001610820 us-gaap:FairValueInputsLevel2Member 2025-07-31 0001610820 us-gaap:FairValueInputsLevel1Member BCTX:WarrantsLiabilityMember 2026-04-30 0001610820 us-gaap:FairValueInputsLevel2Member BCTX:WarrantsLiabilityMember 2026-04-30 0001610820 BCTX:WarrantsLiabilityMember 2026-04-30 0001610820 us-gaap:FairValueInputsLevel1Member BCTX:WarrantsLiabilityMember 2025-07-31 0001610820 us-gaap:FairValueInputsLevel2Member BCTX:WarrantsLiabilityMember 2025-07-31 0001610820 BCTX:WarrantsLiabilityMember 2025-07-31 0001610820 srt:MinimumMember us-gaap:FairValueInputsLevel1Member 2026-04-30 0001610820 srt:MaximumMember us-gaap:FairValueInputsLevel1Member 2026-04-30 0001610820 srt:MinimumMember us-gaap:FairValueInputsLevel1Member 2025-07-31 0001610820 srt:MaximumMember us-gaap:FairValueInputsLevel1Member 2025-07-31 0001610820 2025-01-03 2025-01-03 0001610820 2025-08-25 2025-08-25 0001610820 BCTX:JanuaryTwoThousandTwentySixOfferingMember 2026-01-15 2026-01-15 0001610820 us-gaap:WarrantMember 2026-01-15 0001610820 BCTX:PrefundedWarrantMember 2025-08-01 2026-04-30 0001610820 BCTX:PrefundedWarrantMember 2026-04-30 0001610820 us-gaap:WarrantMember 2026-01-15 2026-01-15 0001610820 BCTX:PlacementAgentWarrantsMember 2026-01-15 0001610820 BCTX:PlacementAgentWarrantsMember 2026-01-15 0001610820 BCTX:PrefundedWarrantMember 2026-01-15 2026-01-21 0001610820 us-gaap:CommonStockMember 2026-01-15 2026-01-21 0001610820 us-gaap:MeasurementInputSharePriceMember us-gaap:WarrantMember 2026-01-15 0001610820 us-gaap:MeasurementInputExercisePriceMember us-gaap:WarrantMember 2026-01-15 0001610820 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2026-01-15 0001610820 BCTX:MeasurementInputAnnualizedVolatilityMember us-gaap:WarrantMember 2026-01-15 0001610820 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2026-01-15 0001610820 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2026-01-15 0001610820 BCTX:PlacementAgentWarrantsMember 2026-01-15 2026-01-15 0001610820 us-gaap:MeasurementInputSharePriceMember BCTX:PlacementAgentWarrantsMember 2026-01-15 0001610820 us-gaap:MeasurementInputExercisePriceMember BCTX:PlacementAgentWarrantsMember 2026-01-15 0001610820 us-gaap:MeasurementInputExpectedTermMember BCTX:PlacementAgentWarrantsMember 2026-01-15 0001610820 BCTX:MeasurementInputAnnualizedVolatilityMember BCTX:PlacementAgentWarrantsMember 2026-01-15 0001610820 us-gaap:MeasurementInputExpectedDividendRateMember BCTX:PlacementAgentWarrantsMember 2026-01-15 0001610820 us-gaap:MeasurementInputRiskFreeInterestRateMember BCTX:PlacementAgentWarrantsMember 2026-01-15 0001610820 BCTX:SharePurchaseWarrantsMember 2025-08-01 2026-04-30 0001610820 BCTX:CompensationWarrantsMember 2025-08-01 2026-04-30 0001610820 BCTX:SharePurchaseWarrantsMember 2025-07-31 0001610820 BCTX:SharePurchaseWarrantsMember 2026-04-30 0001610820 BCTX:CompensationWarrantsMember 2025-07-31 0001610820 BCTX:CompensationWarrantsMember 2026-04-30 0001610820 BCTX:SharePurchaseWarrantsMember BCTX:WarrantOneMember 2026-04-30 0001610820 BCTX:SharePurchaseWarrantsMember BCTX:WarrantTwoMember 2026-04-30 0001610820 BCTX:SharePurchaseWarrantsMember BCTX:WarrantThreeMember 2026-04-30 0001610820 BCTX:SharePurchaseWarrantsMember BCTX:WarrantFourMember 2026-04-30 0001610820 BCTX:SharePurchaseWarrantsMember BCTX:WarrantFiveMember 2026-04-30 0001610820 BCTX:SharePurchaseWarrantsMember BCTX:WarrantSixMember 2026-04-30 0001610820 BCTX:SharePurchaseWarrantsMember BCTX:WarrantSevenMember 2026-04-30 0001610820 BCTX:CompensationWarrantsMember BCTX:WarrantOneMember 2026-04-30 0001610820 BCTX:CompensationWarrantsMember BCTX:WarrantTwoMember 2026-04-30 0001610820 BCTX:CompensationWarrantsMember BCTX:WarrantThreeMember 2026-04-30 0001610820 BCTX:CompensationWarrantsMember BCTX:WarrantFourMember 2026-04-30 0001610820 BCTX:CompensationWarrantsMember BCTX:WarrantFiveMember 2026-04-30 0001610820 BCTX:CompensationWarrantsMember BCTX:WarrantSixMember 2026-04-30 0001610820 BCTX:CompensationWarrantsMember BCTX:WarrantSevenMember 2026-04-30 0001610820 BCTX:CompensationWarrantsMember BCTX:WarrantEightMember 2026-04-30 0001610820 srt:MinimumMember 2026-04-30 0001610820 srt:MaximumMember 2026-04-30 0001610820 srt:MinimumMember 2025-07-31 0001610820 srt:MaximumMember 2025-07-31 0001610820 srt:MinimumMember 2025-08-01 2026-04-30 0001610820 srt:MaximumMember 2025-08-01 2026-04-30 0001610820 srt:MinimumMember 2024-08-01 2025-07-31 0001610820 srt:MaximumMember 2024-08-01 2025-07-31 0001610820 BCTX:BriaProWarrantMember 2023-08-31 0001610820 BCTX:BriaProWarrantMember 2026-04-30 0001610820 srt:MinimumMember BCTX:BriaProWarrantMember 2023-08-31 0001610820 srt:MaximumMember BCTX:BriaProWarrantMember 2023-08-31 0001610820 srt:MinimumMember BCTX:BriaProWarrantMember 2023-08-31 2023-08-31 0001610820 srt:MaximumMember BCTX:BriaProWarrantMember 2023-08-31 2023-08-31 0001610820 srt:MinimumMember BCTX:BriaProWarrantMember 2025-08-01 2026-04-30 0001610820 srt:MaximumMember BCTX:BriaProWarrantMember 2025-08-01 2026-04-30 0001610820 BCTX:BriaProWarrantMember 2023-08-31 2023-08-31 0001610820 BCTX:BriaProWarrantMember 2025-08-01 2026-04-30 0001610820 srt:MaximumMember BCTX:StockOptionPlanMember 2022-08-02 2022-08-02 0001610820 BCTX:StockOptionPlanMember 2026-04-30 0001610820 BCTX:StockOptionPlanMember 2026-02-01 2026-02-01 0001610820 BCTX:BriaProOptionsMember 2026-04-30 0001610820 BCTX:BriaProTherapeuticsCorpMember 2025-08-01 2026-04-30 0001610820 BCTX:StockOptionPlanMember 2025-07-31 0001610820 BCTX:StockOptionPlanMember 2024-08-01 2025-07-31 0001610820 BCTX:StockOptionPlanMember 2025-08-01 2026-04-30 0001610820 BCTX:StockOptionPlanMember 2025-08-01 2025-08-01 0001610820 BCTX:StockOptionPlanMember 2026-02-01 0001610820 BCTX:ExercisePriceFivePointFiveNineMember 2026-04-30 0001610820 BCTX:ExercisePriceFivePointFiveNineMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceOneTwoPointFiveZeroMember 2026-04-30 0001610820 BCTX:ExercisePriceOneTwoPointFiveZeroMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceSixZeroPointZeroZeroMember 2026-04-30 0001610820 BCTX:ExercisePriceSixZeroPointZeroZeroMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceNineZeroFourPointFiveZeroMember 2026-04-30 0001610820 BCTX:ExercisePriceNineZeroFourPointFiveZeroMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceOneZeroSevenFourPointZeroZeroMember 2026-04-30 0001610820 BCTX:ExercisePriceOneZeroSevenFourPointZeroZeroMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceNineZeroSevenPointNineSevenMember 2026-04-30 0001610820 BCTX:ExercisePriceNineZeroSevenPointNineSevenMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceSevenZeroSixPointFiveZeroMember 2026-04-30 0001610820 BCTX:ExercisePriceSevenZeroSixPointFiveZeroMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceOneOneTwoSixPointFiveZeroMember 2026-04-30 0001610820 BCTX:ExercisePriceOneOneTwoSixPointFiveZeroMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceOneTwoSevenZeroPointFiveZeroMember 2026-04-30 0001610820 BCTX:ExercisePriceOneTwoSevenZeroPointFiveZeroMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceOneZeroSevenFourPointEightThreeMember 2026-04-30 0001610820 BCTX:ExercisePriceOneZeroSevenFourPointEightThreeMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointZeroNineThreeThreeMember BCTX:BriaProOptionsMember 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointZeroNineThreeThreeMember BCTX:BriaProOptionsMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointOneOneZeroEightMember BCTX:BriaProOptionsMember 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointOneOneZeroEightMember BCTX:BriaProOptionsMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointZeroNineEightFourMember BCTX:BriaProOptionsMember 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointZeroNineEightFourMember BCTX:BriaProOptionsMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointZeroSevenTwoNineMember BCTX:BriaProOptionsMember 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointZeroSevenTwoNineMember BCTX:BriaProOptionsMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointOneOneSixTwoMember BCTX:BriaProOptionsMember 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointOneOneSixTwoMember BCTX:BriaProOptionsMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointOneThreeOneZeroMember BCTX:BriaProOptionsMember 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointOneThreeOneZeroMember BCTX:BriaProOptionsMember 2025-08-01 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointOneOneSixFiveMember BCTX:BriaProOptionsMember 2026-04-30 0001610820 BCTX:ExercisePriceZeroPointOneOneSixFiveMember BCTX:BriaProOptionsMember 2025-08-01 2026-04-30 0001610820 us-gaap:RestrictedStockUnitsRSUMember 2025-07-31 0001610820 us-gaap:RestrictedStockUnitsRSUMember 2025-08-01 2026-04-30 0001610820 us-gaap:RestrictedStockUnitsRSUMember 2026-04-30 0001610820 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2025-09-24 2025-09-24 0001610820 us-gaap:RestrictedStockUnitsRSUMember 2025-09-24 2025-09-24 0001610820 us-gaap:RestrictedStockUnitsRSUMember BCTX:BriaProTherapeuticsCorpMember 2025-07-31 0001610820 us-gaap:RestrictedStockUnitsRSUMember BCTX:BriaProTherapeuticsCorpMember 2025-08-01 2026-04-30 0001610820 us-gaap:RestrictedStockUnitsRSUMember BCTX:BriaProTherapeuticsCorpMember 2026-04-30 0001610820 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember BCTX:BriaProTherapeuticsCorpMember 2026-04-01 2026-04-01 0001610820 us-gaap:RestrictedStockUnitsRSUMember BCTX:BriaProTherapeuticsCorpMember 2026-04-01 2026-04-01 0001610820 us-gaap:RestrictedStockUnitsRSUMember BCTX:BriaProTherapeuticsCorpMember 2026-04-01 0001610820 us-gaap:PerformanceSharesMember 2025-07-31 0001610820 us-gaap:PerformanceSharesMember 2025-08-01 2026-04-30 0001610820 us-gaap:PerformanceSharesMember 2026-04-30 0001610820 us-gaap:PerformanceSharesMember 2025-08-01 2025-08-01 0001610820 us-gaap:PerformanceSharesMember 2025-08-01 0001610820 srt:OfficerMember 2025-08-01 0001610820 srt:ChiefFinancialOfficerMember 2025-08-01 0001610820 srt:DirectorMember 2025-09-24 2025-09-24 0001610820 srt:DirectorMember 2025-09-24 0001610820 srt:ChiefFinancialOfficerMember us-gaap:PerformanceSharesMember 2025-08-01 2026-04-30 0001610820 BCTX:NationalCancerInstituteMember 2025-08-25 2025-08-25 0001610820 us-gaap:SubsequentEventMember BCTX:JuneTwoThousandTwentySixOfferingMember 2026-06-02 2026-06-02 0001610820 us-gaap:SubsequentEventMember BCTX:JuneTwoThousandTwentySixOfferingMember 2026-06-02 0001610820 BCTX:PlacementAgentWarrantsMember us-gaap:SubsequentEventMember 2026-06-02 0001610820 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2026-06-02 iso4217:USD shares iso4217:USD shares BCTX:Segment pure false Q3 --07-31 0001610820

Unlimited

10-Q true 2026-04-30 2026 false 001-40101 BRIACELL THERAPEUTICS CORP. A1 47-1099599 235 15th Street, Suite 300 West Vancouver BC V7T 2X1 604 921-1810 Common shares, no par value BCTX NASDAQ Warrants to purchase common shares, no par value BCTXW NASDAQ Warrants to purchase common shares, no par value BCTXZ NASDAQ Warrants to purchase common shares, no par value BCTXL NASDAQ Yes Yes Non-accelerated Filer true true false false 8699787

6880221

10493808

15924204

7372473

2588749 2060295

25393174

19926576

750982

524278

173072

184525

348997

296819

405085

717508

1678136

1723130

27071310

21649706

2174437

3283703

1416059

694285

3590496

3977988

71854

337672

71854

337672

7250487

1883906

117117225

101739923

11202809 10316140 30216165 17719026

-138684

-649099

-546795

-134339456

-111755564

23408960

17334046

27071310

21649706

5966673

4810196

18704005

14160314

1654121

1518059

4770998

4490216

7620794

6328255

23475003

18650530

-7620794

-6328255

-23475003

-18650530

186970

-9762

430205

69310

-123242

-175826

-265818

-366024

137830

-64303

-62738

-171126

-176837

-7237055

-6224929

-22812276

-18392033

-72548

-98027

-228384

-171536

-7164507

-6126902

-22583892

-18220497

-0.99

-16.42

-5.73

-67.08

7250487

373067

3942959

271639

7250487

373067

3942959

271639

7250487

117117225

10896682

30216165

-138684

-127174949

-702631

30213808

432207

-126080

126080

-7164507

-72548

-7237055

7250487

117117225

11202809

30216165

-138684

-134339456

-649099

23408960

1883906

101739923

10316140

17719026

-138684

-111755564

-546795

17334046

1012749

1039051

4327530

15377302

12497139

27874441

-126080

126080

-22583892

-228384

-22812276

7250487

117117225

11202809

30216165

-138684

-134339456

-649099

23408960

294699

85451119

10091325

5736454

-138684

-97537292

-376031

3226891

224815

44268

316845

8571406

6142970

14714376

-6126902

-98027

-6224929

655812

94022525

10316140

11879424

-138684

-103664194

-474058

11941153

121907

72166414

9189261

1844296

-138684

-85443697

-302522

-2684932

1126879

44934 6437 1239367 -418352 821015

482534

20616744

10453480

31070224

-18220497

-171536

-18392033

655812

94022525

10316140

11879424

-138684

-103664194

-474058

11941153

-22812276

-18392033

11453

143204

74871

68517

1012749

776879

-171126

-176837

-265818

-366024

137830

-216031 466820

-1109266

-3891577

721774

1111053

-22692452

-20038075

127049

15781000

7372473

260000

255000

-8795576

-255000

821015

27874441

31070224

27874441

31891239

-3613587

11598164

10493808

862089

6880221

12460253

<p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zqLTY7EGwhNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">NOTE 1: GENERAL AND GOING CONCERN <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) was incorporated under the Business Corporations Act (British Columbia) on July 26, 2006 and is listed on the Toronto Stock Exchange (“TSX”) under the symbol “BCT”. The Company also trades on the Nasdaq Capital Market (“NASDAQ”) under the symbols “BCTX”, “BCTXW” “BCTXZ”, and “BCTXL”.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">b.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">BriaCell Therapeutics Corp. (“Briacell” or the “Company”) is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body’s own immune system to recognize and destroy cancer cells. The Company is currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. Bria-IMT™ is currently under Fast Track Designation by the U.S. Food and Drug Administration (the “FDA”) intended to accelerate the review process of novel treatments that address unmet medical needs. Positive completion of the pivotal study, following review by FDA, could lead to full approval of the Bria-IMT™ immune checkpoint inhibitor combination in metastatic breast cancer. A completed Bria-IMT™ Phase 2 combination study with retifanlimab (an anti-PD1 antibody manufactured by Incyte) confirmed tolerability and early efficacy. BriaCell reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer with a median overall survival of 13.4 months in BriaCell’s metastatic breast cancer patients vs. 6.7-9.8 months for similar patients reported in the literature in its Phase 2 study of Bria-IMT™ combination study with retifanlimab at the 2025 American Society of Clinical Oncology (ASCO) meeting. BriaCell is also developing personalized off-the-shelf immunotherapies, Bria-OTS™ and Bria-OTS+™, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer including breast cancer, prostate cancer, lung cancer, and melanoma. BriaCell has an ongoing Phase 1/2 Study of Bria-OTS™, also known as Bria-BRES™, in metastatic breast cancer. BriaCell also has an open Investigational New Drug application (IND) for the clinical evaluation of Bria-BRES+™, the first of the Bria-OTS+™ enhanced personalized off-the-shelf immunotherapies approved for clinical evaluation in patients with advanced metastatic breast cancer. BriaCell also has completed manufacturing of the Bria-PROS+™ cell line for prostate cancer.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">c.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Basis of presentation of the financial statements:</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the U.S Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments consisting of a normal recurring nature which are necessary for a fair presentation of the financial position, operating results, and cash flows for the periods presented.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report for the year ended July 31, 2025, filed with the SEC on October 16, 2025. The interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">d.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Going concern</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company continues to devote substantially all of its efforts toward research and development activities. In the course of such activities, the Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company’s accumulated deficit as of April 30, 2026 was $134,339,456 and negative cash flows from operating activities during the nine-month period ended April 30, 2026 was $22,692,452. The Company is planning to finance its operations by exploring additional sources of capital and financing, while managing its existing working capital resources. During the year ended July 31, 2025, the Company raised $50.9 million in gross proceeds from equity financings and, in January 2026, completed a public offering generating approximately $30 million in gross proceeds. However, the Company’s ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to continue to obtain the necessary financing to meet its obligations arising from normal business operations when they come due. The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company not be able to continue as a going concern.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">e. </td> <td style="font: 10pt Times New Roman, Times, Serif">The Company has two wholly-owned U.S. subsidiaries: (i) BriaCell Therapeutics Corp. (“BTC”), which was incorporated in April 3, 2014, under the laws of the state of Delaware, and (ii) BTC has a wholly-owned subsidiary, Sapientia Pharmaceuticals, Inc. (“Sapientia”), which was incorporated in September 20, 2012, under the laws of the state of Delaware. The Company also has two Canadian subsidiaries (i) BriaPro Therapeutics Corp, (“BriaPro”) which was incorporated on May 15, 2023, under the Business Corporations Act (British Columbia). BriaPro was established to complete a plan of arrangement spinout transaction in August 2023, pursuant to which certain pipeline assets of the Company were spun-out to BriaPro, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the “BriaPro Assets”), resulting in a two-third (2/3) owned subsidiary of the Company with the remaining one-third (1/3) held by the Company’s shareholders (the “Amalgamation” and the “Amalgamation Agreement”) – see also note 1(f) below. (Sapientia and BTC and BriaPro together, the “Subsidiaries”), and (ii) Briacell Therapeutics AU Pty Ltd, a wholly owned subsidiary in Australia, established on January 28, 2026, which is currently inactive.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">f.</td> <td style="font: 10pt Times New Roman, Times, Serif">On February 18, 2026, the Company and BriaPro, announced that they have entered into a definitive purchase agreement (the “Purchase Agreement”) pursuant to which BriaPro has agreed to purchase BriaCell’s exclusive license to develop and commercialize Soluble CD80 (“sCD80”) as a biologic agent for the treatment of cancer and other associated assets (the “Transaction”). Under the terms of the Purchase Agreement, BriaPro gains the worldwide rights to develop and commercialize sCD80 as a therapeutic agent for the treatment of cancer, while the University of Maryland, Baltimore County (“UMBC”) holds all rights, title and interest in the inventions and the patent, except for certain rights retained by the United States Government. BriaPro will pay 2% royalties to UMBC upon the commercialization of the product plus other development costs. As part of the Transaction, BriaCell will make available to BriaPro up to $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityPeriodicPayment_pn6n6_c20260218__20260218__us-gaap--LineOfCreditFacilityAxis__custom--BriaCellTherapeuticsMember_zscvRUx7eGi6" title="Fund for Research and development">3 million to fund research and development efforts (the “Credit Facility”). Each drawdown under the Credit Facility will be subject to BriaCell’s approval regarding the use of funds. As consideration for the transfer of the exclusive license and the Credit Facility, BriaPro issued to BriaCell 23,972,589 common shares, increasing BriaCell’s interest in BriaPro to approximately 78% post-transaction. On March 5, 2026, the disinterested shareholders of BriaPro approved the Transaction and the Transaction closed on March 31, 2026.</td></tr> </table> BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

-134339456

-22692452

50900000

30000000

0.02

3000000

23972589

0.78

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES a. Use of estimates: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Significant estimates include the determination of the fair value of warrant liabilities, which are measured using valuation models that require assumptions such as share price volatility, expected term, and risk-free interest rates. Changes in these inputs could materially impact the valuation of the warrant liability and the amounts recognized in the condensed consolidated financial statements.</td></tr> </table> b. Prepaid expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has prepaid certain expenses in respect of its pivotal phase III trial and estimates the period over which such expenses will be incurred. Amounts estimated to be expenses in more than 12 months have been classified to long-term prepaid expenses.</td></tr> </table> c. The useful life of property and equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Property and equipment are depreciated over their useful lives. Useful lives are based on management’s estimates of the period that the assets will be used which are periodically reviewed for continued appropriateness. Changes to estimates can result in significant variations in the amounts charged to the consolidated statement of operations and comprehensive loss in specific periods.</td></tr> </table> d. Investment equity method: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Investments in entities over which the Company does not have a controlling financial interest but has significant influence are accounted for using the equity method, with the Company’s share of losses reported in the loss from equity method investments on the statements of operation and comprehensive loss. The Company has a <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20260430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BCTherapeuticsMember_zoexHqBHmawg" title="Investment equity method percentage">69% interest in BC Therapeutics. Management evaluates whether it has control over the investee in accordance with the guidance of ASC 810, which requires judgment to assess factors such as power over significant activities of the investee, exposure to variable returns, and the ability to affect those returns. Based on this evaluation, management determines whether control or significant influence is present for accounting purposes.</td></tr> </table> e. Segment reporting: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company manages its business activities on a consolidated basis and operates as one reportable segment. The Company’s operations are focused on the research and development of its immunotherapy product candidates and related supporting activities. The Chief Executive Officer is identified as the Company’s Chief Operating Decision Maker (“CODM”).</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The accounting policies of the segment are the same as those used in the condensed consolidated financial statements. The CODM evaluates the Company’s performance and allocates resources using consolidated financial information, including net loss and cash flow forecasts. The Company’s significant expenses, which consist primarily of research and development and general and administrative expenses, are consistent with the captions presented on the consolidated statements of operations and comprehensive loss.</td></tr> </table> f. Share-based compensation: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company accounts for share-based compensation in accordance with ASC No. 718, “Compensation – Stock Compensation”, which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the award is recognized as an expense over the requisite service periods, which is the vesting period of the respective award, on a straight-line basis when the only condition to vesting is continued service.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has selected the Black-Scholes option-pricing model as the most appropriate fair value method for its option awards. The Company recognizes forfeitures of equity-based awards as they occur. Restricted share units use the share price on the grant date to determine the fair value of the restricted share unit award.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">For performance-based stock units (“PSUs”) that do not contain market conditions, the Company measures the grant-date fair value using the closing price of the common stock on the date of grant. Compensation cost for these awards is recognized over the requisite service period based on the number of awards that are expected to vest. Management evaluates the probability of achieving the applicable performance conditions each reporting period and adjusts the expense recognition accordingly.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of the date of this report, the Company has issued stock options, RSUs, and PSUs that do not contain market conditions.</td></tr> </table> g. Recently issued and adopted accounting standards: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As an “emerging growth company,” the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election. The pronouncements below relate to standards that impact the Company.</td></tr> </table> BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (Cont.) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In January 2025, the FASB issued ASU 2025-01 - Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. This standard amends the guidance issued in 2024 to confirm that all public business entities must present the required expense-disaggregation disclosures in annual periods beginning after December 15, 2026, and interim periods within annual periods beginning after December 15, 2027. The ASU is effective for years beginning after those dates, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Because the amendment only affects disclosure timing, the Company does not expect this standard to have a material impact on its financial statements and disclosures.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In June 2025, the FASB issued ASU 2025-03 - Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in a Variable-Interest Entity. This standard clarifies that when a business combination is effected primarily by exchanging equity interests and the legal acquiree is a variable-interest entity (“VIE”) that meets the definition of a business, entities must identify the accounting acquirer using the factors in ASC 805-10-55-12 through 55-15, rather than relying solely on the VIE consolidation model. The ASU is effective for years beginning after December 15, 2026, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of this standard on its financial statements and disclosures.</td></tr> </table>

a. Use of estimates: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Significant estimates include the determination of the fair value of warrant liabilities, which are measured using valuation models that require assumptions such as share price volatility, expected term, and risk-free interest rates. Changes in these inputs could materially impact the valuation of the warrant liability and the amounts recognized in the condensed consolidated financial statements.</td></tr> </table>

b. Prepaid expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has prepaid certain expenses in respect of its pivotal phase III trial and estimates the period over which such expenses will be incurred. Amounts estimated to be expenses in more than 12 months have been classified to long-term prepaid expenses.</td></tr> </table>

c. The useful life of property and equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Property and equipment are depreciated over their useful lives. Useful lives are based on management’s estimates of the period that the assets will be used which are periodically reviewed for continued appropriateness. Changes to estimates can result in significant variations in the amounts charged to the consolidated statement of operations and comprehensive loss in specific periods.</td></tr> </table>

d. Investment equity method: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Investments in entities over which the Company does not have a controlling financial interest but has significant influence are accounted for using the equity method, with the Company’s share of losses reported in the loss from equity method investments on the statements of operation and comprehensive loss. The Company has a <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20260430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BCTherapeuticsMember_zoexHqBHmawg" title="Investment equity method percentage">69% interest in BC Therapeutics. Management evaluates whether it has control over the investee in accordance with the guidance of ASC 810, which requires judgment to assess factors such as power over significant activities of the investee, exposure to variable returns, and the ability to affect those returns. Based on this evaluation, management determines whether control or significant influence is present for accounting purposes.</td></tr> </table>

0.69

e. Segment reporting: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company manages its business activities on a consolidated basis and operates as one reportable segment. The Company’s operations are focused on the research and development of its immunotherapy product candidates and related supporting activities. The Chief Executive Officer is identified as the Company’s Chief Operating Decision Maker (“CODM”).</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The accounting policies of the segment are the same as those used in the condensed consolidated financial statements. The CODM evaluates the Company’s performance and allocates resources using consolidated financial information, including net loss and cash flow forecasts. The Company’s significant expenses, which consist primarily of research and development and general and administrative expenses, are consistent with the captions presented on the consolidated statements of operations and comprehensive loss.</td></tr> </table>

f. Share-based compensation: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company accounts for share-based compensation in accordance with ASC No. 718, “Compensation – Stock Compensation”, which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the award is recognized as an expense over the requisite service periods, which is the vesting period of the respective award, on a straight-line basis when the only condition to vesting is continued service.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has selected the Black-Scholes option-pricing model as the most appropriate fair value method for its option awards. The Company recognizes forfeitures of equity-based awards as they occur. Restricted share units use the share price on the grant date to determine the fair value of the restricted share unit award.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">For performance-based stock units (“PSUs”) that do not contain market conditions, the Company measures the grant-date fair value using the closing price of the common stock on the date of grant. Compensation cost for these awards is recognized over the requisite service period based on the number of awards that are expected to vest. Management evaluates the probability of achieving the applicable performance conditions each reporting period and adjusts the expense recognition accordingly.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of the date of this report, the Company has issued stock options, RSUs, and PSUs that do not contain market conditions.</td></tr> </table>

g. Recently issued and adopted accounting standards: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As an “emerging growth company,” the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election. The pronouncements below relate to standards that impact the Company.</td></tr> </table> BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (Cont.) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In January 2025, the FASB issued ASU 2025-01 - Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. This standard amends the guidance issued in 2024 to confirm that all public business entities must present the required expense-disaggregation disclosures in annual periods beginning after December 15, 2026, and interim periods within annual periods beginning after December 15, 2027. The ASU is effective for years beginning after those dates, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Because the amendment only affects disclosure timing, the Company does not expect this standard to have a material impact on its financial statements and disclosures.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In June 2025, the FASB issued ASU 2025-03 - Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in a Variable-Interest Entity. This standard clarifies that when a business combination is effected primarily by exchanging equity interests and the legal acquiree is a variable-interest entity (“VIE”) that meets the definition of a business, entities must identify the accounting acquirer using the factors in ASC 805-10-55-12 through 55-15, rather than relying solely on the VIE consolidation model. The ASU is effective for years beginning after December 15, 2026, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of this standard on its financial statements and disclosures.</td></tr> </table>

NOTE 3: INVESTMENT IN BC THERAPEUTICS INC. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On December 21, 2021, the Company and BC Therapeutics, Inc. (“BC Therapeutics” or “the Investee”) entered a share purchase agreement (“SPA”), pursuant to which the Company initially provided a loan of $<span id="xdx_901_eus-gaap--PaymentsToAcquireLoansReceivable_c20211221__20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_znoRa35BcbLk" title="Initial loan">300,000 to BC Therapeutics, with no interest to be paid. Subsequently, in accordance with the SPA, this loan was converted into an equity investment in BC Therapeutics at a rate of $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_zteuLyiiJZyc" title="Share price">1.25 per share, resulting in a <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BCTherapeuticsMember_znWXAqkTHNrg" title="Ownership percentage">37.5% ownership interest (“Initial Investment”).</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pursuant to the SPA (“Initial Investment”), Briacell also received two options to invest an additional $<span id="xdx_907_eus-gaap--PaymentsToAcquireInvestments_c20211221__20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__us-gaap--AwardTypeAxis__custom--TwoOptionsMember_zWZgezURHJrd">225,000 per option at $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__us-gaap--AwardTypeAxis__custom--TwoOptionsMember_zWsAaxpOqyEf">1.25 per BC Therapeutics share (“BC Therapeutic Options”) through to June 30, 2024. In accordance with ASC 321 and ASC 815, the BC Therapeutics Options were valued at $<span id="xdx_90A_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20211221__20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_zuZ2mf74yNji">76,350 in accordance with the Black Scholes Option Price Model, using the following assumptions: Share price: $<span id="xdx_905_eus-gaap--SharePrice_iI_c20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_zOZTW5nD2O0a" title="Share price">1.25, Exercise price: $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_z4QSeUdlmo6k" title="Exercise price">1.25, Dividend yield: <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20211221__20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_zVupDxYxOEJ3" title="Dividend yield">0%, Risk free interest rate: <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20211221__20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_zKukvnbYYMkh" title="Risk free interest rate">4.902%, Volatility: <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20211221__20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_z19MnZN2QhW" title="Volatility">100%, and expected lives ranging from <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211221__20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__srt--RangeAxis__srt--MinimumMember_z5ALzC0HEqWe" title="Expected lives">0.16 years to <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211221__20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__srt--RangeAxis__srt--MaximumMember_zfpNg0gYiU11" title="Expected lives">0.53 years. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Following the Initial Investment, the Company and BC Therapeutics signed three amendments, each time, extending the BC Therapeutic Options expiry date and increasing the amount of capital that the Company can invest at the same price per share of $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20211221__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__us-gaap--AwardTypeAxis__custom--TwoOptionsMember_zonC4StbjX0i">1.25. BC Therapeutic Options now expire on June 2027. The most recent BC Therapeutic Option received was valued at $<span id="xdx_90B_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20250801__20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__us-gaap--AwardTypeAxis__custom--JuneTwoThousandTwentySevenMember_z6zj46kSV11d" title="Fair value of option">193,829 in accordance with the Black Scholes Option Price Model, using the following assumptions: Share price: $<span id="xdx_902_eus-gaap--SharePrice_iI_c20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__us-gaap--AwardTypeAxis__custom--JuneTwoThousandTwentySevenMember_zUIofu2gRtsa">1.25, Exercise price: $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__us-gaap--AwardTypeAxis__custom--JuneTwoThousandTwentySevenMember_zAPZJXAyNWoh">1.25, Dividend yield: <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250801__20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__us-gaap--AwardTypeAxis__custom--JuneTwoThousandTwentySevenMember_zcZx8USvqXkh">0%, Risk free interest rate: <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250801__20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__us-gaap--AwardTypeAxis__custom--JuneTwoThousandTwentySevenMember_z83kcRoQEb13">3.527%, Volatility: <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250801__20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__us-gaap--AwardTypeAxis__custom--JuneTwoThousandTwentySevenMember_zSG8bwu7KAr7">100% and expiry date: <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember__us-gaap--AwardTypeAxis__custom--JuneTwoThousandTwentySevenMember_ztQtV9tzHir1" title="Expiry date">1.41 years. This amount has been included in the Company’s investment with a corresponding credit to unrealized gain on investment in the condensed consolidated statements of operations and comprehensive loss. During the nine-month period ended April 30, 2026, the Company exercised the BC Therapeutic Options totaling $260,000 and received 208,000 shares. At each exercise date, the portion of the BC Therapeutic Options being exercised was revalued using the Black-Scholes Option Price Model and the change in fair value was recorded in the condensed consolidated statements of operations and comprehensive loss. On April 30, 2026, the Company revalued the remaining balance of the BC Therapeutic Options in accordance with the Black Scholes Option Price Model, using the following assumptions: Share price: $<span id="xdx_909_eus-gaap--SharePrice_iI_c20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_z21MTNsJB9sh" title="Share price">1.25, Exercise price: $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_zdCdRuOmgIec" title="Exercise price">1.25, Dividend yield: <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260430__20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_z0RtJCcCQTt" title="Dividend yield">0%, Risk free interest rate: <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260430__20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_zuT4xM4A6vlg" title="Risk free interest rate">3.885%, Volatility: <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260430__20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_z0RzC5byKewe" title="Volatility">100% and expiry date: <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260430__20260430__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--BCTherapeuticsMember_zGGk9xYxMpu5" title="Expiry date">1.17 years. The change in fair value was recorded in the condensed consolidated statements of operations and comprehensive loss. BC Therapeutics has a board of four representatives, with two representatives appointed by BriaCell and two representatives appointed by the existing shareholders. All significant decisions related to BC Therapeutics require the approval of at least a majority of the board members. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of April 30, 2026, the Company holds 892,000 of the <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20260430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BCTherapeuticsMember_zefN131tEiTd" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20260430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BCTherapeuticsMember_zQnSnsb4e96c" title="Common stock, shares outstanding">1,292,000 issued and outstanding shares in BC Therapeutics, representing a <span id="xdx_90B_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zTffip91lUwi" title="Equity interest percentage">69.04% ownership interest. In addition, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_pid_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zUeS4YBYJxhb" title="Available for purchase shares">288,000 shares remain available for purchase under the Third BC Therapeutics Option at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zwQKpKKcenXe" title="Exercise price">1.25 per share; these options expire on June 30, 2027.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In accordance with ASC 810, the Company continues to account for the investment under the equity method of accounting as the Company does not exercise control over BC Therapeutics.</td></tr> </table> BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 3: INVESTMENT IN BC THERAPEUTICS INC. (Cont.) Changes in the Company’s equity investment in BC Therapeutics is summarized as follows: SCHEDULE OF CHANGES IN INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; font-weight: bold">Balance – August 1, 2024</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquityMethodInvestments_iS_c20240801__20250731__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zdC2UR3CWQq" style="width: 16%; font-weight: bold; text-align: right" title="Beginning balance">418,490</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Funding (including the value of the BC Therapeutics Options)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--PaymentsToAcquireInvestments_c20240801__20250731__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_z4W4C8ytcNu" style="text-align: right" title="Funding (including the value of the BC Therapeutics Options)">330,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt">Share of losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--IncomeLossFromEquityMethodInvestments_c20240801__20250731__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_z8Fu2WQpAym9" style="border-bottom: Black 1pt solid; text-align: right" title="Share of losses">(224,212</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Balance – July 31, 2025</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_987_eus-gaap--EquityMethodInvestments_iS_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zEjWZIGIk90g" style="font-weight: bold; text-align: right" title="Beginning balance">524,278</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Exercise of BC Therapeutic Options during the period (funding) </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PaymentsToAcquireInvestments_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zqgPNpukaRZ" style="text-align: right" title="Funding">260,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Fair value of BC Therapeutics Options on February 1, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Funding (including the value of the BC Therapeutics Options)"><p id="xdx_989_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zBCKkpoeSK61" style="margin: 0" title="BC Therapeutics Option">193,829</td><td style="text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Change in fair value during the period</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_986_ecustom--GainLossOnDerivativeInstrumentsNotDesignatedAsHedgingInstruments_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_z1rO2cZHIuUa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value during the period">(55,999</td> <td style="font: 10pt Times New Roman, Times, Serif">) </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Share of losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--IncomeLossFromEquityMethodInvestments_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zaGlE8ioPIK6" style="border-bottom: Black 1pt solid; text-align: right" title="Share of losses">(171,126</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Balance – April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityMethodInvestments_iE_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_ziIE2c3iTpC5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Ending balance">750,982</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_89B_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zTkW6y01egyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The following amounts represent the Company’s <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20260430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BCTherapeuticsMember_zz61ok5RGCW2" title="Investment equity method percentage">69% share of the assets of BC Therapeutics (July 31, 2025 – <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20250731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BCTherapeuticsMember_zLJWAbKTbemd" title="Investment equity method percentage">63.1%): SCHEDULE OF ASSETS AND LIABILITIES OF BC THERAPEUTICS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zbePR5ApkmS6" style="border-bottom: Black 1pt solid; text-align: center">As of April 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzltE_zh6ofe2hRl0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; font-weight: bold; text-align: left; padding-bottom: 1pt">Current assets: Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,117</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzltE_zh0lyPU68Eak" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Net assets</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,117</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table>

300000

1.25

0.375

225000

1.25

76350

1.25

0.04902

P0Y1M28D

P0Y6M10D

1.25

193829

1.25

0.03527

P1Y4M28D

260000

208000

1.25

0.03885

P1Y2M1D

892000

1292000

0.6904

288000

1.25

Changes in the Company’s equity investment in BC Therapeutics is summarized as follows: SCHEDULE OF CHANGES IN INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; font-weight: bold">Balance – August 1, 2024</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquityMethodInvestments_iS_c20240801__20250731__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zdC2UR3CWQq" style="width: 16%; font-weight: bold; text-align: right" title="Beginning balance">418,490</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Funding (including the value of the BC Therapeutics Options)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--PaymentsToAcquireInvestments_c20240801__20250731__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_z4W4C8ytcNu" style="text-align: right" title="Funding (including the value of the BC Therapeutics Options)">330,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt">Share of losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--IncomeLossFromEquityMethodInvestments_c20240801__20250731__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_z8Fu2WQpAym9" style="border-bottom: Black 1pt solid; text-align: right" title="Share of losses">(224,212</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Balance – July 31, 2025</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_987_eus-gaap--EquityMethodInvestments_iS_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zEjWZIGIk90g" style="font-weight: bold; text-align: right" title="Beginning balance">524,278</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Exercise of BC Therapeutic Options during the period (funding) </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PaymentsToAcquireInvestments_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zqgPNpukaRZ" style="text-align: right" title="Funding">260,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Fair value of BC Therapeutics Options on February 1, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Funding (including the value of the BC Therapeutics Options)"><p id="xdx_989_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zBCKkpoeSK61" style="margin: 0" title="BC Therapeutics Option">193,829</td><td style="text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Change in fair value during the period</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_986_ecustom--GainLossOnDerivativeInstrumentsNotDesignatedAsHedgingInstruments_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_z1rO2cZHIuUa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value during the period">(55,999</td> <td style="font: 10pt Times New Roman, Times, Serif">) </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Share of losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--IncomeLossFromEquityMethodInvestments_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zaGlE8ioPIK6" style="border-bottom: Black 1pt solid; text-align: right" title="Share of losses">(171,126</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Balance – April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityMethodInvestments_iE_c20250801__20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_ziIE2c3iTpC5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Ending balance">750,982</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table>

418490

330000

-224212

524278

260000

193829

-55999

-171126

750982

<p id="xdx_89B_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zTkW6y01egyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The following amounts represent the Company’s <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20260430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BCTherapeuticsMember_zz61ok5RGCW2" title="Investment equity method percentage">69% share of the assets of BC Therapeutics (July 31, 2025 – <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20250731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BCTherapeuticsMember_zLJWAbKTbemd" title="Investment equity method percentage">63.1%): SCHEDULE OF ASSETS AND LIABILITIES OF BC THERAPEUTICS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260430__us-gaap--BusinessAcquisitionAxis__custom--BCTherapeuticsMember_zbePR5ApkmS6" style="border-bottom: Black 1pt solid; text-align: center">As of April 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzltE_zh6ofe2hRl0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; font-weight: bold; text-align: left; padding-bottom: 1pt">Current assets: Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,117</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzltE_zh0lyPU68Eak" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Net assets</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,117</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table>

0.69

0.631

2117

NOTE 4: CONTINGENT LIABILITIES AND COMMITMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">BriaPro Warrants</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Upon the exercise of certain BriaCell warrants that were outstanding at the time of the Amalgamation Agreement with BriaPro (“Briacell Legacy Warrants”), BriaCell shall, as agent for BriaPro, collect and pay to BriaPro an amount based on an agreed formula. As of April 30, 2026, this amount totaled of up to $<span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260430__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--AmalgamationAgreementMember_zlvh7OINQOA4" title="Warrants amount">133,320 and is eliminated on consolidation. Pursuant to the Amalgamation Agreement, each BriaCell warrant in issuance at the time of the Amalgamation (“Briacell Legacy Warrant”) shall, in accordance with its terms, entitle the holder thereof to receive, upon the exercise thereof, one BriaCell Share (and post Reverse Splits, as defined below– 150 Briacell Shares) and one BriaPro Share for the original exercise price. Warrants issued by the Company, subsequent to the Arrangement are not subject to the terms above. Upon the exercise of 150 BriaCell Legacy Warrants (post Reverse Splits), BriaCell shall, as agent for BriaPro, collect and pay to BriaPro an amount for each one (1) BriaPro Share so issued that is equal to the exercise price under the 150 BriaCell Legacy Warrants multiplied by the fair market value of one (1) BriaPro Share at the Effective Date divided by the total fair market value of one (1) BriaCell Share and one (1) BriaPro Share at the Effective Date (“BriaPro Warrant Shares”). On a Reverse Split basis, as of April 30, 2026, <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260430__us-gaap--TypeOfArrangementAxis__custom--AmalgamationAgreementMember_zjKBZE3n4Xd9" title="Warrants exercisable">27,984 Briacell Legacy Warrants are exercisable into <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--TypeOfArrangementAxis__custom--AmalgamationAgreementMember__dei--LegalEntityAxis__custom--BriaCellTherapeuticsMember_zYMp7BuWjiF9" title="Warrants shares">27,984 Briacell Shares and <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--TypeOfArrangementAxis__custom--AmalgamationAgreementMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_zRlr9mi3GqKf" title="Warrants shares">4,197,831 BriaPro Shares.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">b.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Lease</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has a month-to-month commitment for office and lab space in Philadelphia, PA, costing approximately $43,500 per month. </td></tr> </table>

133320

27984

4197831

43500

NOTE 5: FAIR VALUE MEASUREMENTS <p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zOPRaThONIXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of April 30, 2026 and July 31, 2025: SCHEDULE OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE ON A RECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zrWCUYZLWsKf" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">6,880,221</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zg7rMAOcqWwj" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zPedrcMiG4Sh" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">6,880,221</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zF3nekj9D4Ei" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">10,493,808</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zrbFwgjylDji" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_z1Z6ECrFyFne" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">10,493,808</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term investments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_z7dIOnryUWp5" style="text-align: right" title="Total assets measured at fair value">15,924,204</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_z6Jxf6WHAM0f" style="text-align: right" title="Total assets measured at fair value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_zRiSeWvF46Lb" style="text-align: right" title="Total assets measured at fair value">15,924,204</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_zE2RHkXOO2Kg" style="text-align: right" title="Total assets measured at fair value">7,372,473</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_zzuQVfNztj5j" style="text-align: right" title="Total assets measured at fair value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_zcpZPMLiGKw8" style="text-align: right" title="Total assets measured at fair value">7,372,473</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVZr0TzWkLOe" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total assets measured at fair value">22,804,425</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zNk08JjNHINg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20260430_zhfiZi3QxNva" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total assets measured at fair value">22,804,425</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zCNKYNUMt8dg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">17,866,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztPW8Z4IXlW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20250731_zcTo63lbbPXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">17,866,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Warrants liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_zFscLBtAoQ34" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_zAC1KoCtdFp9" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">71,854</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_zvZllzwhPHce" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">71,854</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_z2qwelCeaWzi" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">151,586</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_zQI1f5gqsCF9" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">186,086</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_ztBC91D39E0h" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">337,672</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWr2rXcoQF1b" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">-</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxyVLaWTfWZ1" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">71,854</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430_z4oOjD0kifj6" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">71,854</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4fLIadtPB7b" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">151,586</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zh86V1CiKIf6" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">186,086</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731_zXSvpBlCrE9b" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">337,672</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 5: FAIR VALUE MEASUREMENTS (Cont.) The Company classifies cash and cash equivalents and the liability in respect of publicly traded warrants within Level 1 because we use quoted market prices in active markets. As of April 30, 2026 and July 31, 2025, the Company held Level 1 short-term investments measured using quoted prices in active markets. As of April 30, 2026, the Company’s short-term investments had coupon rates ranging from <span id="xdx_900_ecustom--InterestRateOnInvestmentPercentage_iI_pid_dp_uPure_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--RangeAxis__srt--MinimumMember_zjahxqnitkTl" title="Interest rate on investment percentage">1.13% to <span id="xdx_90B_ecustom--InterestRateOnInvestmentPercentage_iI_pid_dp_uPure_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--RangeAxis__srt--MaximumMember_zzUqvTL2Fsci" title="Interest rate on investment percentage">5.59%. As of July 31, 2025, the Company’s short-term investments had coupon rates ranging from <span id="xdx_909_ecustom--InterestRateOnInvestmentPercentage_iI_pid_dp_uPure_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--RangeAxis__srt--MinimumMember_zqdpuaDyWDj" title="Interest rate on investment percentage">3.00% to <span id="xdx_907_ecustom--InterestRateOnInvestmentPercentage_iI_pid_dp_uPure_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--RangeAxis__srt--MaximumMember_zE5vjd1OUn1c" title="Interest rate on investment percentage">5.51%. The fair value of the warrant liability for non-public warrants is measured using inputs other than quoted prices included in Level 1 that are observable for the liability either directly or indirectly, and thus are classified as Level 2 financial instruments.

<p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zOPRaThONIXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of April 30, 2026 and July 31, 2025: SCHEDULE OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE ON A RECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zrWCUYZLWsKf" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">6,880,221</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zg7rMAOcqWwj" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zPedrcMiG4Sh" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">6,880,221</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zF3nekj9D4Ei" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">10,493,808</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zrbFwgjylDji" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_z1Z6ECrFyFne" style="border-bottom: Black 1pt solid; width: 6%; text-align: right" title="Total assets measured at fair value">10,493,808</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term investments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_z7dIOnryUWp5" style="text-align: right" title="Total assets measured at fair value">15,924,204</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_z6Jxf6WHAM0f" style="text-align: right" title="Total assets measured at fair value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_zRiSeWvF46Lb" style="text-align: right" title="Total assets measured at fair value">15,924,204</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_zE2RHkXOO2Kg" style="text-align: right" title="Total assets measured at fair value">7,372,473</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_zzuQVfNztj5j" style="text-align: right" title="Total assets measured at fair value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByAssetClassAxis__us-gaap--ShortTermInvestmentsMember_zcpZPMLiGKw8" style="text-align: right" title="Total assets measured at fair value">7,372,473</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVZr0TzWkLOe" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total assets measured at fair value">22,804,425</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zNk08JjNHINg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20260430_zhfiZi3QxNva" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total assets measured at fair value">22,804,425</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zCNKYNUMt8dg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">17,866,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztPW8Z4IXlW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20250731_zcTo63lbbPXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">17,866,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Warrants liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_zFscLBtAoQ34" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_zAC1KoCtdFp9" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">71,854</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_zvZllzwhPHce" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">71,854</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_z2qwelCeaWzi" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">151,586</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_zQI1f5gqsCF9" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">186,086</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantsLiabilityMember_ztBC91D39E0h" style="border-bottom: Black 1pt solid; text-align: right" title="Total liabilities measured at fair value">337,672</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWr2rXcoQF1b" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">-</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxyVLaWTfWZ1" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">71,854</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260430_z4oOjD0kifj6" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">71,854</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4fLIadtPB7b" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">151,586</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zh86V1CiKIf6" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">186,086</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250731_zXSvpBlCrE9b" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Total liabilities measured at fair value">337,672</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

6880221

10493808

15924204

7372473

22804425

17866281

71854

151586

186086

337672

71854

151586

186086

337672

0.0113 0.0559 0.0300 0.0551

NOTE 6: SHAREHOLDERS’ EQUITY a. Authorized share capital The authorized share capital consists of an unlimited number of common shares with no par value. b. Issued share capital <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Reverse Stock Split:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 3, 2025, the Company’s board of directors approved a reverse stock split of the Company’s common shares on a 1-for-15 basis, which became effective on January 24, 2025 and on August 25, 2025 (the “Effective Date”), the Company effected a reverse stock split of its common shares on a 1-for-10 basis (the “Reverse Splits”). </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As a result of the Reverse Splits, every one hundred and fifty (150) pre-split common shares issued and outstanding were automatically combined into one (1) new common share. No fractional common shares were issued in connection with the Reverse Splits. Instead, any fractional common shares resulting from the January 2025 Reverse Split were deemed to have been tendered to the Company for cancellation for no consideration.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">All share and per share amounts in the accompanying condensed consolidated financial statements and related notes have been retroactively adjusted to reflect both the January 2025 Reverse Split and the August 2025 Reverse Split for all periods presented.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(ii)</td> <td style="font: 10pt Times New Roman, Times, Serif">The Company issued the following shares during the nine-month period ended April 30, 2026: On January 15, 2026, the Company closed a public offering for the purchase and sale of 5,366,726 units of the Company for aggregate gross proceeds of approximately $30.0 million before deducting placement agent fees and other offering expenses (the “January 2026 Offering”). Each unit consisted of one common share (or one pre-funded warrant (“Pre-Funded Warrants”) in lieu thereof) and one warrant to purchase one common share of the Company at a combined purchase price of $5.59 per unit. 4,327,530 common shares and 1,039,196 Pre-Funded Warrants were issued. The warrants have an exercise price of $6.93 per share, are immediately exercisable, and expire five years from the date of issuance (“January 2026 Warrants”). The aggregate exercise price of the Pre-Funded Warrants, except for a nominal exercise price of $0.001 per share, was pre-funded to the Company and, consequently, no additional consideration (other than the nominal exercise price of $<span id="xdx_90E_ecustom--OtherThanNominalExercisePricePerShare_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zsPeexdp79ca" title="Other than nominal exercise price per share">0.001 per share) shall be required to be paid by the holder to affect any exercise of the Pre-Funded Warrants. The fair value of the Pre-Funded Warrants was based on the Company’s share price as at the corresponding valuation date. The common shares (or Pre-Funded Warrants) and January 2026 Warrants were purchased together in the offering but were issued separately. Total issuance costs associated with the offering were approximately $2,125,100, excluding the fair value of placement agent warrants. In connection with the January 2026 Offering, the Company issued <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260115__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zaZOviH9Djdg" title="Warrant issued">161,001 placement agent warrants. The placement agent warrants are immediately exercisable at an exercise price of $8.39 per share and expire five years from the date of issuance. Between January 15, 2026 and January 21, 2026, the <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260115__20260121__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zGKNtZgvdKc9" title="Issuance of units, shares">1,039,196 Pre-Funded Warrants were exercised on a cashless basis into <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20260115__20260121__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsl1YgIFvIzb" title="Cashless exercise">1,039,051 common shares. The fair value of the <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260115__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZxtf8PkEbmh" title="Warrants issued">5,366,726 January 2026 Warrants was determined to be $13,103,125 (gross, before deducting share issuance costs) using the Black-Scholes option pricing model, with the following assumptions: share price – $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zmu3NPwlhKDc" title="Warrants and rights outstanding, measurement input">3.15; exercise price – $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z4jLsq35Cwgh" title="Warrants and rights outstanding, measurement input">6.93; expected life – <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zTlX5TIXXmKj" title="Warrants and rights outstanding, measurement input">5 years; annualized volatility – <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputAnnualizedVolatilityMember_z5XQG8ZOuaHj" title="Warrants and rights outstanding, measurement input">123%; dividend yield – <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zesATmOvfLKk" title="Warrants and rights outstanding, measurement input">0%; risk-free rate – <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVYpKQFrvJfl" title="Warrants and rights outstanding, measurement input">3.762%. The fair value of the <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260115__20260115__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentWarrantsMember_z4PThGKCkYY2" title="Sale of stock, number of shares issued">161,001 placement agent warrants was determined to be $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_c20260115__20260115__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentWarrantsMember_zLbHxb0mI9i4" title="Gross roceeds from issuance of warrants">572,334 using the Black-Scholes option pricing model, with the following assumptions: share price – $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zq4FcSjwstAc" title="Warrants and rights outstanding, measurement input">4.49; exercise price – $<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z4DxbTPTGJzl" title="Warrants and rights outstanding, measurement input">8.39; expected life – <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zfTLJq7yler3" title="Warrants and rights outstanding, measurement input">5 years; annualized volatility – <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputAnnualizedVolatilityMember_zEZgMrCPv2di" title="Warrants and rights outstanding, measurement input">123%; dividend yield – <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxXJW086tMw5" title="Warrants and rights outstanding, measurement input">0%; risk-free rate – <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260115__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zDn5Qflruoe3" title="Warrants and rights outstanding, measurement input">3.762%. The amounts were credited to the warrant reserve at the date of the January 2026 Offering.</td></tr> </table> BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 6: SHAREHOLDERS’ EQUITY (Cont.) c. Share Purchase Warrants <p id="xdx_89A_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_z6CjO6Bu5iZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of changes in share purchase warrants for the nine-month period ending April 30, 2026 is presented below: SUMMARY OF CHANGES IN WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of warrants outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; text-align: justify">Balance, July 31, 2025</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zWQpEuEKN2S2" style="width: 16%; font-weight: bold; text-align: right" title="Number of warrants outstanding, beginning balance">1,653,914</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zyk7ejRdKc8a" style="width: 16%; font-weight: bold; text-align: right" title="Weighted average exercise price, beginning balance">58.27</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zZBQQOHhbi7f" style="text-align: right" title="Number of warrants outstanding, expired">(26,324</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpired_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zqmwxOLnyte6" style="text-align: right" title="Weighted average exercise price, expired">794.29</td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Granted in the January 2026 Offering</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zGntR9qUqOr6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding, granted">5,366,726</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceGranted_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zZfqOASWFDgk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, granted">6.93</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Balance, April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zPGgXJbggaL6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of warrants outstanding, ending balance">6,994,316</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_znTJ3L5KrXjf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, ending balance">16.11</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(ii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of April 30, 2026, warrants outstanding were as follows:</td></tr> </table> <p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zxGDDrn6t797" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 83%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercisable At April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_fKCop_zTHQYFft8zdb" style="width: 16%; text-align: right" title="Number of warrants outstanding">(*)27,820</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_zyn1y2g4s5h1" style="width: 16%; text-align: right" title="Exercise Price">928.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_ztSIHHXywyP2" style="width: 16%; text-align: right" title="Number of warrants exercisable">27,820</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 40%; text-align: center"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_zLqlmkB03pjf" title="Expiry Date">December 7, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zXDhSyoR6QF7" style="text-align: right" title="Number of warrants outstanding">16,019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zWw7xkQUrNY9" style="text-align: right" title="Exercise Price">316.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_z9lvNvzgrqde" style="text-align: right" title="Number of warrants exercisable">16,019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zDAVI2vQIOf6" title="Expiry Date">November 17, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_ziumRKjN43Y4" style="text-align: right" title="Number of warrants outstanding">27,753</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zhuSejcpQlK3" style="text-align: right" title="Exercise Price">127.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zhUntMHcsvMg" style="text-align: right" title="Number of warrants exercisable">27,753</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zTYJcB8JzMrg" title="Expiry Date">October 2, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zQV91emaL2V8" style="text-align: right" title="Number of warrants outstanding">49,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zMncEWn0oi74" style="text-align: right" title="Exercise Price">140.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zLx4pQtyvC75" style="text-align: right" title="Number of warrants exercisable">49,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zAxnQLafhPP1" title="Expiry Date">December 12, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zGhgsnu1vDIj" style="text-align: right" title="Number of warrants outstanding">306,665</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_z1QXWY2XvXP8" style="text-align: right" title="Exercise Price">52.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zClxBJBz5jUh" style="text-align: right" title="Number of warrants exercisable">306,665</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zckS07rTaKrd" title="Expiry Date">April 28, 2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zgCsqdKcaDGa" style="text-align: right" title="Number of warrants outstanding">1,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zwDIXc3ViBog" style="text-align: right" title="Exercise Price">15.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zBxk8GIDNEm7" style="text-align: right" title="Number of warrants exercisable">1,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zTXMBBQgxZu8" title="Expiry Date">July 15, 2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_zxqMiSH704q6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding">5,366,726</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_zpL0O8JXTGKc" style="padding-bottom: 1pt; text-align: right" title="Exercise price">6.93</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_zgCATvI1jU6b" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants exercisable">5,366,726</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_zQbN42a4FHj8" title="Expiry date">January 15, 2031</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_ztZEUE20jOe5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding">6,994,316</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zOMWH2elzk3i" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants exercisable">6,994,316</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(*)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Briacell Legacy Warrants – see note 1(e) and note 4(a) </td></tr> </table> d. Compensation Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A summary of changes in compensation warrants for the nine-month period ended April 30, 2026 is presented below:</td></tr> </table> <p id="xdx_895_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zrZysivHxBK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SUMMARY OF CHANGES IN WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">Number of warrants outstanding</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted average exercise price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: justify">Balance, July 31, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zP25CIsLUED3" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of warrants outstanding, beginning balance">28,072</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_ze1QcZgRPQRi" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted average exercise price, beginning balance">93.54</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Expired</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zIJtcDDCuy84" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, expired">(147</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpired_iN_di_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_z0epCLCxUYF1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, expired">751.22</td> <td style="font: 10pt Times New Roman, Times, Serif"></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted in the January 2026 Offering</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zwkKzQHfU8U5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, granted">161,001</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceGranted_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zfWds4DSXlQh" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted">8.39</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Balance, April 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zTa8iwryrhzk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, ending balance">188,926</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zmxLdLVxxEi4" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance">20.46</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(ii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of April 30, 2026, compensation warrants outstanding were as follows:</td></tr> </table> <p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zZKBtodEVKjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercisable At April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_fKCop_z2YYTAlGqSsf" style="width: 16%; text-align: right" title="Number of warrants outstanding">(*)164</td><td style="width: 1%; text-align: left"></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_z1noGdPJVrHa" style="width: 16%; text-align: right" title="Exercise Price">928.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_zjAbRCNbPEL7" style="width: 16%; text-align: right" title="Number of warrants exercisable">164</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 40%; text-align: center"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_zbJ0u1xBMaFj" title="Expiry Date">June 7, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zUgn9PcFgkv6" style="text-align: right" title="Number of warrants outstanding">333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zXjgLRowVnR3" style="text-align: right" title="Exercise Price">348.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_z15EpA21zqba" style="text-align: right" title="Number of warrants exercisable">333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zKZJ7r1hNBJe" title="Expiry Date">May 17, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zWrCHPuX1WL7" style="text-align: right" title="Number of warrants outstanding">4,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zuTPCi2JaNXb" style="text-align: right" title="Exercise Price">129.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zAqnuwcx4O1k" style="text-align: right" title="Number of warrants exercisable">4,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zOPptgypGKjb" title="Expiry Date">September 12, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_z4Ybm9ciMom9" style="text-align: right" title="Number of warrants outstanding">1,709</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zg7JLl1Gs4Ma" style="text-align: right" title="Exercise Price">182.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zZhFs20aUTUb" style="text-align: right" title="Number of warrants exercisable">1,709</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zKOn9JcZQWNf" title="Expiry Date">October 2, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zLEFJeo4l5s4" style="text-align: right" title="Number of warrants outstanding">2,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zHMwxyvZTQD2" style="text-align: right" title="Exercise Price">140.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zXCjTrFRaCPi" style="text-align: right" title="Number of warrants exercisable">2,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zKKd4NXQ7Ekb" title="Expiry Date">December 12, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_z6hKv0QKX1rh" style="text-align: right" title="Number of warrants outstanding">3,812</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zb8ISwYFiDz4" style="text-align: right" title="Exercise Price">50.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zKsXqsSL7MN1" style="text-align: right" title="Number of warrants exercisable">3,812</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_z3rXHDTD2sdd" title="Expiry Date">February 5, 2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_z5iw9KIkn847" style="text-align: right" title="Number of warrants outstanding">15,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_znWQkc1cLkx2" style="text-align: right" title="Exercise Price">56.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_ziSbklXSRNC8" style="text-align: right" title="Number of warrants exercisable">15,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_zi7cg7P0unQ1" title="Expiry Date">April 28, 2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantEightMember_zyFpv9OXRIsh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding">161,001</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantEightMember_zCzCCmLUM4ma" style="padding-bottom: 1pt; text-align: right" title="Exercise price">8.39</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantEightMember_zTi7ywQhMP68" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants exercisable">161,001</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantEightMember_zGo5fR2TgA2" title="Expiry date">January 15, 2031</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zgDvFzS51BRc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of warrants outstanding">188,926</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zqIeCOGTnQSj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of warrants exercisable">188,926</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(*)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Briacell Legacy Warrants – see note 1(e) and note 4(a)</td></tr> </table> BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 6: SHAREHOLDERS’ EQUITY (Cont.) e. Warrant liability continuity The following table presents the summary of the changes in the fair value of the warrants: SCHEDULE OF CHANGE IN FAIR VALUE OF WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants liability</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Balance as of August 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKWcDFFOFYNb" style="width: 16%; text-align: right" title="Warrant liability, beginning balance">337,672</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Change in fair value during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueAdjustmentOfWarrants_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbNttR30TSze" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value during the period">(265,818</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance as of April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJwi3123TU9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant liability, ending balance">71,854</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The key inputs used in the valuation of the non-public warrants as of April 30, 2026 and at July 31, 2025 were as follows: SCHEDULE OF VALUATION OF NON PUBLIC OFFERING BROKER WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">April 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">July 31, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Share price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.18</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.50</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20260430__srt--RangeAxis__srt--MinimumMember_zSrAyxAGrmac" title="Exercise price">796.88-<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20260430__srt--RangeAxis__srt--MaximumMember_zUyu8sqoBNfa" title="Exercise price">928.50</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20250731__srt--RangeAxis__srt--MinimumMember_zMgSvfhvaeme" title="Exercise price">796.88-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20250731__srt--RangeAxis__srt--MaximumMember_zPM2Q9kuJO44" title="Exercise price">928.50 </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Expected life (years)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260430__srt--RangeAxis__srt--MinimumMember_zyoA4GdmbsRe" title="Expected life">0.10-<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260430__srt--RangeAxis__srt--MaximumMember_ziIecPmE6kRg" title="Expected life">0.60</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240801__20250731__srt--RangeAxis__srt--MinimumMember_zLf331IxOR3" title="Expected life">0.57-<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240801__20250731__srt--RangeAxis__srt--MaximumMember_zCZG6EeRtZwa" title="Expected life">1.35</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250801__20260430__srt--RangeAxis__srt--MinimumMember_zvq3jRIh9lyg" title="Volatility">67-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250801__20260430__srt--RangeAxis__srt--MaximumMember_zWZXVq61WEW3" title="Volatility">146</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240801__20250731__srt--RangeAxis__srt--MinimumMember_zrOpmpNcXXLi" title="Volatility">157-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240801__20250731__srt--RangeAxis__srt--MaximumMember_zuVDqd6iysL6" title="Volatility">209</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Dividend yield</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">0</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">0</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Risk free rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250801__20260430__srt--RangeAxis__srt--MinimumMember_z3k9ssEkkP9g" title="Risk free rate">3.67-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250801__20260430__srt--RangeAxis__srt--MaximumMember_zmB2t8ZKHVOb" title="Risk free rate">3.69</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.10</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> </table> The key inputs used in the valuation of the of the BriaPro Warrant Shares as of April 30, 2026 were as follows: SCHEDULE OF BRIA PRO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">August 31, 2023 (Effective Date)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">April 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Share price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0365</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0365</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exercise price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MinimumMember_z0e77Fue33Ma" title="Exercise price">0.0206-<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MaximumMember_zAzQA2H04eaj" title="Exercise price">0.0308</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember_zhFfidPUw79e" title="Exercise price">0.0318</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected life (years)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230831__20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MinimumMember_zBmNZ2yOPFp5" title="Expected life (years)">2.21-<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230831__20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MaximumMember_z0NLKVA8lY13" title="Expected life (years)">3.27</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MinimumMember_zvOQzUtsGAn3" title="Expected life (years)">0.10-<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MaximumMember_zmHz8c24WMPg" title="Expected life (years)">0.60</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">Volatility</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230831__20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember_zysXJShURZSi" title="Volatility">100</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MinimumMember_z8B42wqJBR37" title="Volatility">67-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MaximumMember_zwsoP2DhDrM8" title="Volatility">146</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dividend yield</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230831__20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember_z2bJ5V3xQlLe" title="Dividend yield">0</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember_zHx58R2AYm6l" title="Dividend yield">0</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk free rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230831__20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember_zu0XyUvoyid5" title="Risk free rate">4.40</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MinimumMember_zzj7ZujauOX1" title="Risk free rate">2.28-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MaximumMember_zrfT3JKdCdA4" title="Risk free rate">2.42</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> </table> BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

1-for-15

1-for-10

5366726

30000000.0

5.59

4327530

1039196

6.93

P5Y

0.001 0.001

2125100

161001

8.39

P5Y

1039196

1039051

5366726

13103125

3.15

6.93

123

3.762

161001

572334

4.49

8.39

123

3.762

<p id="xdx_89A_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_z6CjO6Bu5iZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of changes in share purchase warrants for the nine-month period ending April 30, 2026 is presented below: SUMMARY OF CHANGES IN WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of warrants outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; text-align: justify">Balance, July 31, 2025</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zWQpEuEKN2S2" style="width: 16%; font-weight: bold; text-align: right" title="Number of warrants outstanding, beginning balance">1,653,914</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zyk7ejRdKc8a" style="width: 16%; font-weight: bold; text-align: right" title="Weighted average exercise price, beginning balance">58.27</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zZBQQOHhbi7f" style="text-align: right" title="Number of warrants outstanding, expired">(26,324</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpired_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zqmwxOLnyte6" style="text-align: right" title="Weighted average exercise price, expired">794.29</td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Granted in the January 2026 Offering</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zGntR9qUqOr6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding, granted">5,366,726</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceGranted_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zZfqOASWFDgk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, granted">6.93</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Balance, April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zPGgXJbggaL6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of warrants outstanding, ending balance">6,994,316</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_znTJ3L5KrXjf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, ending balance">16.11</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table>

1653914

58.27

26324

794.29

5366726

6.93

6994316

16.11

<p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zxGDDrn6t797" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 83%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercisable At April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_fKCop_zTHQYFft8zdb" style="width: 16%; text-align: right" title="Number of warrants outstanding">(*)27,820</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_zyn1y2g4s5h1" style="width: 16%; text-align: right" title="Exercise Price">928.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_ztSIHHXywyP2" style="width: 16%; text-align: right" title="Number of warrants exercisable">27,820</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 40%; text-align: center"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_zLqlmkB03pjf" title="Expiry Date">December 7, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zXDhSyoR6QF7" style="text-align: right" title="Number of warrants outstanding">16,019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zWw7xkQUrNY9" style="text-align: right" title="Exercise Price">316.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_z9lvNvzgrqde" style="text-align: right" title="Number of warrants exercisable">16,019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zDAVI2vQIOf6" title="Expiry Date">November 17, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_ziumRKjN43Y4" style="text-align: right" title="Number of warrants outstanding">27,753</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zhuSejcpQlK3" style="text-align: right" title="Exercise Price">127.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zhUntMHcsvMg" style="text-align: right" title="Number of warrants exercisable">27,753</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zTYJcB8JzMrg" title="Expiry Date">October 2, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zQV91emaL2V8" style="text-align: right" title="Number of warrants outstanding">49,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zMncEWn0oi74" style="text-align: right" title="Exercise Price">140.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zLx4pQtyvC75" style="text-align: right" title="Number of warrants exercisable">49,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zAxnQLafhPP1" title="Expiry Date">December 12, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zGhgsnu1vDIj" style="text-align: right" title="Number of warrants outstanding">306,665</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_z1QXWY2XvXP8" style="text-align: right" title="Exercise Price">52.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zClxBJBz5jUh" style="text-align: right" title="Number of warrants exercisable">306,665</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zckS07rTaKrd" title="Expiry Date">April 28, 2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zgCsqdKcaDGa" style="text-align: right" title="Number of warrants outstanding">1,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zwDIXc3ViBog" style="text-align: right" title="Exercise Price">15.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zBxk8GIDNEm7" style="text-align: right" title="Number of warrants exercisable">1,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zTXMBBQgxZu8" title="Expiry Date">July 15, 2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_zxqMiSH704q6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding">5,366,726</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_zpL0O8JXTGKc" style="padding-bottom: 1pt; text-align: right" title="Exercise price">6.93</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_zgCATvI1jU6b" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants exercisable">5,366,726</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_zQbN42a4FHj8" title="Expiry date">January 15, 2031</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_ztZEUE20jOe5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding">6,994,316</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--SharePurchaseWarrantsMember_zOMWH2elzk3i" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants exercisable">6,994,316</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(*)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Briacell Legacy Warrants – see note 1(e) and note 4(a) </td></tr> </table>

-27820

928.50

27820

2026-12-07

16019

316.50

16019

2029-11-17

27753

127.50

27753

2029-10-02

49333

140.63

49333

2029-12-12

306665

52.50

306665

2030-04-28

1200000

15.00

1200000

2030-07-15

5366726

6.93

5366726

2031-01-15

6994316

<p id="xdx_895_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zrZysivHxBK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SUMMARY OF CHANGES IN WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">Number of warrants outstanding</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">Weighted average exercise price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: justify">Balance, July 31, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zP25CIsLUED3" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of warrants outstanding, beginning balance">28,072</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_ze1QcZgRPQRi" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted average exercise price, beginning balance">93.54</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Expired</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zIJtcDDCuy84" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, expired">(147</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpired_iN_di_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_z0epCLCxUYF1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, expired">751.22</td> <td style="font: 10pt Times New Roman, Times, Serif"></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted in the January 2026 Offering</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zwkKzQHfU8U5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, granted">161,001</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceGranted_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zfWds4DSXlQh" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted">8.39</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Balance, April 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zTa8iwryrhzk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants outstanding, ending balance">188,926</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zmxLdLVxxEi4" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending balance">20.46</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

28072

93.54

147

-751.22

161001

8.39

188926

20.46

<p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zZKBtodEVKjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercisable At April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_fKCop_z2YYTAlGqSsf" style="width: 16%; text-align: right" title="Number of warrants outstanding">(*)164</td><td style="width: 1%; text-align: left"></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_z1noGdPJVrHa" style="width: 16%; text-align: right" title="Exercise Price">928.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_zjAbRCNbPEL7" style="width: 16%; text-align: right" title="Number of warrants exercisable">164</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 40%; text-align: center"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantOneMember_zbJ0u1xBMaFj" title="Expiry Date">June 7, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zUgn9PcFgkv6" style="text-align: right" title="Number of warrants outstanding">333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zXjgLRowVnR3" style="text-align: right" title="Exercise Price">348.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_z15EpA21zqba" style="text-align: right" title="Number of warrants exercisable">333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantTwoMember_zKZJ7r1hNBJe" title="Expiry Date">May 17, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zWrCHPuX1WL7" style="text-align: right" title="Number of warrants outstanding">4,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zuTPCi2JaNXb" style="text-align: right" title="Exercise Price">129.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zAqnuwcx4O1k" style="text-align: right" title="Number of warrants exercisable">4,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantThreeMember_zOPptgypGKjb" title="Expiry Date">September 12, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_z4Ybm9ciMom9" style="text-align: right" title="Number of warrants outstanding">1,709</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zg7JLl1Gs4Ma" style="text-align: right" title="Exercise Price">182.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zZhFs20aUTUb" style="text-align: right" title="Number of warrants exercisable">1,709</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFourMember_zKOn9JcZQWNf" title="Expiry Date">October 2, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zLEFJeo4l5s4" style="text-align: right" title="Number of warrants outstanding">2,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zHMwxyvZTQD2" style="text-align: right" title="Exercise Price">140.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zXCjTrFRaCPi" style="text-align: right" title="Number of warrants exercisable">2,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantFiveMember_zKKd4NXQ7Ekb" title="Expiry Date">December 12, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_z6hKv0QKX1rh" style="text-align: right" title="Number of warrants outstanding">3,812</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zb8ISwYFiDz4" style="text-align: right" title="Exercise Price">50.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_zKsXqsSL7MN1" style="text-align: right" title="Number of warrants exercisable">3,812</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSixMember_z3rXHDTD2sdd" title="Expiry Date">February 5, 2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_z5iw9KIkn847" style="text-align: right" title="Number of warrants outstanding">15,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_znWQkc1cLkx2" style="text-align: right" title="Exercise Price">56.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_ziSbklXSRNC8" style="text-align: right" title="Number of warrants exercisable">15,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantSevenMember_zi7cg7P0unQ1" title="Expiry Date">April 28, 2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantEightMember_zyFpv9OXRIsh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding">161,001</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantEightMember_zCzCCmLUM4ma" style="padding-bottom: 1pt; text-align: right" title="Exercise price">8.39</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantEightMember_zTi7ywQhMP68" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants exercisable">161,001</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--WarrantEightMember_zGo5fR2TgA2" title="Expiry date">January 15, 2031</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zgDvFzS51BRc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of warrants outstanding">188,926</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260430__us-gaap--StatementEquityComponentsAxis__custom--CompensationWarrantsMember_zqIeCOGTnQSj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of warrants exercisable">188,926</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(*)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Briacell Legacy Warrants – see note 1(e) and note 4(a)</td></tr> </table>

-164

928.50

164

2026-06-07

333

348.00

333

2029-05-17

4108

129.38

4108

2029-09-12

1709

182.81

1709

2029-10-02

2466

140.63

2466

2029-12-12

3812

50.00

3812

2030-02-05

15333

56.50

15333

2030-04-28

161001

8.39

161001

2031-01-15

188926

The following table presents the summary of the changes in the fair value of the warrants: SCHEDULE OF CHANGE IN FAIR VALUE OF WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants liability</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Balance as of August 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKWcDFFOFYNb" style="width: 16%; text-align: right" title="Warrant liability, beginning balance">337,672</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Change in fair value during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueAdjustmentOfWarrants_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbNttR30TSze" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value during the period">(265,818</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance as of April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20250801__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJwi3123TU9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant liability, ending balance">71,854</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

337672

-265818

71854

The key inputs used in the valuation of the non-public warrants as of April 30, 2026 and at July 31, 2025 were as follows: SCHEDULE OF VALUATION OF NON PUBLIC OFFERING BROKER WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">April 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">July 31, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Share price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.18</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.50</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20260430__srt--RangeAxis__srt--MinimumMember_zSrAyxAGrmac" title="Exercise price">796.88-<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20260430__srt--RangeAxis__srt--MaximumMember_zUyu8sqoBNfa" title="Exercise price">928.50</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20250731__srt--RangeAxis__srt--MinimumMember_zMgSvfhvaeme" title="Exercise price">796.88-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20250731__srt--RangeAxis__srt--MaximumMember_zPM2Q9kuJO44" title="Exercise price">928.50 </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Expected life (years)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260430__srt--RangeAxis__srt--MinimumMember_zyoA4GdmbsRe" title="Expected life">0.10-<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260430__srt--RangeAxis__srt--MaximumMember_ziIecPmE6kRg" title="Expected life">0.60</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240801__20250731__srt--RangeAxis__srt--MinimumMember_zLf331IxOR3" title="Expected life">0.57-<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240801__20250731__srt--RangeAxis__srt--MaximumMember_zCZG6EeRtZwa" title="Expected life">1.35</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250801__20260430__srt--RangeAxis__srt--MinimumMember_zvq3jRIh9lyg" title="Volatility">67-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250801__20260430__srt--RangeAxis__srt--MaximumMember_zWZXVq61WEW3" title="Volatility">146</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240801__20250731__srt--RangeAxis__srt--MinimumMember_zrOpmpNcXXLi" title="Volatility">157-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240801__20250731__srt--RangeAxis__srt--MaximumMember_zuVDqd6iysL6" title="Volatility">209</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Dividend yield</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">0</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">0</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Risk free rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250801__20260430__srt--RangeAxis__srt--MinimumMember_z3k9ssEkkP9g" title="Risk free rate">3.67-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250801__20260430__srt--RangeAxis__srt--MaximumMember_zmB2t8ZKHVOb" title="Risk free rate">3.69</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.10</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> </table>

4.18

7.50

796.88 928.50 796.88 928.50

P0Y1M6D

P0Y7M6D

P0Y6M25D

P1Y4M6D

0.67

1.46

1.57

2.09

0.0367

0.0369

0.0410

The key inputs used in the valuation of the of the BriaPro Warrant Shares as of April 30, 2026 were as follows: SCHEDULE OF BRIA PRO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">August 31, 2023 (Effective Date)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">April 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Share price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0365</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0365</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exercise price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MinimumMember_z0e77Fue33Ma" title="Exercise price">0.0206-<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MaximumMember_zAzQA2H04eaj" title="Exercise price">0.0308</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember_zhFfidPUw79e" title="Exercise price">0.0318</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected life (years)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230831__20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MinimumMember_zBmNZ2yOPFp5" title="Expected life (years)">2.21-<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230831__20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MaximumMember_z0NLKVA8lY13" title="Expected life (years)">3.27</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MinimumMember_zvOQzUtsGAn3" title="Expected life (years)">0.10-<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MaximumMember_zmHz8c24WMPg" title="Expected life (years)">0.60</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">Volatility</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230831__20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember_zysXJShURZSi" title="Volatility">100</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MinimumMember_z8B42wqJBR37" title="Volatility">67-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MaximumMember_zwsoP2DhDrM8" title="Volatility">146</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dividend yield</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230831__20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember_z2bJ5V3xQlLe" title="Dividend yield">0</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember_zHx58R2AYm6l" title="Dividend yield">0</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk free rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230831__20230831__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember_zu0XyUvoyid5" title="Risk free rate">4.40</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MinimumMember_zzj7ZujauOX1" title="Risk free rate">2.28-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250801__20260430__us-gaap--FinancialInstrumentAxis__custom--BriaProWarrantMember__srt--RangeAxis__srt--MaximumMember_zrfT3JKdCdA4" title="Risk free rate">2.42</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> </table>

0.0365

0.0206 0.0308 0.0318

P2Y2M15D

P3Y3M7D

P0Y1M6D

P0Y7M6D

0.67

1.46

0.0440

0.0228

0.0242

NOTE 7: SHARE-BASED COMPENSATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 2, 2022, the Company approved an omnibus equity incentive plan (“Omnibus Plan), which will permit the Company to grant incentive stock options, preferred share units, restricted share units (“RSU’s”), performance-based share units (“PSUs”), and deferred share units (collectively, the “Awards”) for the benefit of any employee, officer, director, or consultant of the Company or any subsidiary of the Company. The maximum number of shares available for issuance under the Omnibus Plan shall not exceed <span id="xdx_900_ecustom--AcquiringPercentageOfIssuedAndOutstandingOfCommonStock_pid_dp_uPure_c20220802__20220802__us-gaap--PlanNameAxis__custom--StockOptionPlanMember__srt--RangeAxis__srt--MaximumMember_z509ld6HR6W2" title="Acquiring percentage of issued and outstanding of common stock">15% of the issued and outstanding Shares, from time to time, less the number of Shares reserved for issuance under all other security-based compensation arrangements of the Company, including the existing Stock Option Plan. On February 9, 2023, the Omnibus Plan was approved by the shareholders.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">b.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following table summarizes the number of options granted to directors, officers, employees and consultants under the option plan for nine-month period ended April 30, 2026 and related information:</td></tr> </table> SUMMARY OF NUMBER OF OPTIONS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average remaining contractual term (in years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Balance as of July 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zm78q6AbN1Ra" style="width: 10%; text-align: right" title="Number of options, beginning balance">13,251</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zJYbEEO80Vm4" style="width: 10%; text-align: right" title="Weighted average exercise price, beginning balance">896.61</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240801__20250731__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zdpRuiJ5FjB7" title="Weighted average remaining contractual term (in years)">1.62</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zkuG9oDdQNj5" style="width: 10%; text-align: right" title="Aggregate intrinsic value, beginning balance"> -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted (i)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_fKGkp_zGpX8P5cznm" style="text-align: right" title="Number of options, granted">328,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_fKGkp_zMlbFlZHC4a8" style="text-align: right" title="Weighted average exercise price, granted">6.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualGranted_dtY_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_fKGkp_zNpLdF0SMdKc" title="Weighted average remaining contractual term (in years), granted">4.70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantedIntrinsicValue_pp0p0_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_fKGkp_zHsCIBdkHOHe" style="text-align: right" title="Aggregate intrinsic value, granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z9luHS1txDHi" style="text-align: right" title="Number of options, expired">(4,477</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zEV4lfsS8L3j" style="text-align: right" title="Weighted average exercise price, expired">636</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zfVnzmHTnQNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, ending balance">337,474</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zGBN4DaNUQIc" title="Weighted average exercise price, ending balance">33.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z31naSJP2EI3" title="Weighted average remaining contractual term (in years)">4.61</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z6ZBVd8dCU18" title="Aggregate intrinsic value, ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable as of April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z4edOvygFnle" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable">22,912</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zN9aJXxYXxWe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, exercisable">403.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zcteMN5qvotj" title="Weighted average remaining contractual term (in years), exercisable">3.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zsIrRPWnMldj" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, exercisable">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif">On August 1, 2025, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250801__20250801__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z1ANDJitJhS4" title="Number of options granted">37,700 stock options to employees and members of the scientific advisory board at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250801__20250801__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zwQZtCRux3Z3" title="Weighted average exercise price, granted">12.50 per share. All options vest quarterly over two years. The options expire on August 1, 2030. The grant-date fair value of the award was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20250801__20250801__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z0vN6OYmsZA4" title="Number of options issued">218,784. The fair value of options granted during the nine-month period ended April 30, 2026 was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z2QBivOFrybl" title="Expected volatility">116%, expected term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zUXv54di4mS" title="Expected term">5.0 years, risk-free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zWa6vt0zYe6a" title="Risk free interest rate">3.98%, dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zBOhSkgQmtbd" title="Dividend yield">0%, and a stock price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zhPayC7Didf4" title="Exercise price">7.50 on the grant date. On February 1, 2026, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zXfwh9nGoE12" title="Number of options granted">291,000 stock options to employees and members of the scientific advisory board at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zYqOwhR6yYB1" title="Weighted average exercise price, granted">5.59 per share. All options vest in equal quarterly installments over two years, with the first vesting date on May 1, 2026. The options expire on February 1, 2031. The grant-date fair value of the award was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z8Sr4odnhQDc" title="Number of options issued">1,031,192. The fair value of options granted was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zIJo10REWhIj" title="Expected volatility">123%, expected term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zcED8kZGaL5b" title="Expected term">5.0 years, risk-free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zL7d6nlvP1ja" title="Risk free interest rate">3.79%, dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z7pXWnH1L504" title="Dividend yield">0%, and a stock price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zGwV1CwhgzP2" title="Exercise price">4.30 on the grant date.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; text-align: left"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">c.</td> <td style="text-align: justify">As of April 30, 2026, there were $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zxNdGmlsKTS7" title="Unrecognized costs">2,069,605 of total unrecognized share-based compensation costs related to stock options, restricted share units (RSUs), and performance share units (PSUs) that are expected to be recognized over a period of up to <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zBiCCljWYT14" title="Share-based compensation expected recognized term">2.25 years.</td></tr> </table> BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 7: SHARE-BASED COMPENSATION (Cont.) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following table summarizes information about the Company’s outstanding and exercisable options granted to employees as of April 30, 2026</td></tr> </table> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zxJTEhUC4aqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options outstanding as of April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average remaining contractual term (years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options exercisable as of April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average remaining contractual term (years)</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_zGee3RbT6is8" title="Exercise price">5.59</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_z4XrorSXbCLl" style="width: 9%; text-align: right" title="Options outstanding">291,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_zEoa4WUtEXek" style="width: 9%; text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">4.75</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_z5ZnkT9SJBv9" style="width: 9%; text-align: right" title="Options exercisable">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_z6Rl2rbOHkH1" style="width: 9%; text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">4.75</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 35%"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_zP6exv5okrdk" title="Expiry date">February 1, 2031</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_zrwUXc8Lzr9a" title="Exercise price">12.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_zmQn9hL6NoG3" style="text-align: right" title="Options outstanding">37,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_zm6ByxQk56G2" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">4.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_z76kCH6jDHu4" style="text-align: right" title="Options exercisable">14,138</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_zQooZ6CesUB7" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">4.25</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_zmSHofEf0299" title="Expiry date">August 1, 2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_zqgZgeTX2whd" title="Exercise price">60.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_zfMPFQ1666c1" style="text-align: right" title="Options outstanding">333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_zqXcdCy5V33c" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">3.70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_z1ra45RHBXEd" style="text-align: right" title="Options exercisable">333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_zb9V1DqmniC3" style="text-align: right" title="Weighted average remaining contractual term (years)">3.70</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_zWxt0qTmvzm5" title="Expiry Date">January 16, 2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_z0l0ORWDAEz8" title="Exercise price">904.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_z68dG9RvVnwi" style="text-align: right" title="Options outstanding">2,663</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_z2F3geYPB8Fb" style="text-align: right" title="Weighted average remaining contractual term (years)">2.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_zNH3B2XZimkl" style="text-align: right" title="Options exercisable">2,663</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_z7u3xZ7MAFtk" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">2.14</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_zJUWfnp7Laii" title="Expiry Date">June 20, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zSnaFOiv0pa4" title="Exercise price">1,074.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zfQOE9w9M8F" style="text-align: right" title="Options outstanding">136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zHJ1KnhtmAGf" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">1.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zCw3C33OzNw" style="text-align: right" title="Options exercisable">136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zRgpGAws8j73" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">1.83</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zKm1GWTVaxw9" title="Expiry Date">February 27, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zWNohmjTSzma" title="Exercise price">907.97</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zHSLUtNcNs78" style="text-align: right" title="Options outstanding">1,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zueqZfcdXxFh" style="text-align: right" title="Weighted average remaining contractual term (years)">1.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zMohb8ziZrR4" style="text-align: right" title="Options exercisable">1,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zuxDy41zCDg7" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">1.26</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zzywUPIlfXpg" title="Expiry Date">August 2, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_zES6TxHpUpZh" title="Exercise price">706.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_zPfKGq84FIL" style="text-align: right" title="Options outstanding">206</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_zm4RNuaYQEwj" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">1.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_zWSBZJbQURmf" style="text-align: right" title="Options exercisable">206</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_z0x3sHESprch" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">1.06</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_zrUeO3HQsvY1" title="Expiry Date">May 20, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zrr7Fka0Y1Zj" title="Exercise price">1,126.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zA18wmi6yg9k" style="text-align: right" title="Options outstanding">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zvCGU76PzuD3" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">0.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zpRfG5t9xe5" style="text-align: right" title="Options exercisable">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zpIQESDlRjwh" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">0.79</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zXmKdUIne0r8" title="Expiry Date">February 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_z03Mzp6rofd9" title="Exercise price">1,270.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_z4Bj8Z7tA86f" style="text-align: right" title="Options outstanding">3,160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_zI6RnvNSrfx5" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">0.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_z2Qw7XiZmxta" style="text-align: right" title="Options exercisable">3,160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_zL8HUdmbqlKc" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">0.75</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_zEBKdqbBWMVi" title="Expiry Date">January 13, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_zkSNvDpmqe81" title="Exercise price">1,074.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_zzf8HwbBsmb7" style="text-align: right" title="Options outstanding">81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_zMWg0ENmhpJ3" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_zc80oA1eskka" style="text-align: right" title="Options exercisable">81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_zSNcbT4HTb0f" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">0.50</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_z5WG16Ws4Wzh" title="Expiry date">November 1, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430_zJisZj3amdJ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">337,474</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430_zgkT0Izi3twe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable">22,912</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">e.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As result of the Arrangement, <span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember_z3ZTVrv9Upxc" title="Options issued and outstanding">1,269,400 BriaPro Options were issued and are outstanding as of April 30, 2026:</td></tr> </table> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BriaProTherapeuticsCorpMember_zkOd7sUU91ll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options outstanding as of April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options exercisable as of April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiry Date</td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineThreeThreeMember_z2CaVp9e3rW2" title="Exercise price">0.0933</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineThreeThreeMember_zN3IWWqDH12h" style="width: 16%; text-align: right" title="Options outstanding">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineThreeThreeMember_z8nTewuNzqQ9" style="width: 16%; text-align: right" title="Options outstanding">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 40%"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineThreeThreeMember_z2iKDFRjZ8rk" title="Expiry date">June 20, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneZeroEightMember_zn4vnIUJEhoc" title="Exercise price">0.1108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneZeroEightMember_z41XXJzktckd" style="text-align: right" title="Options outstanding">21,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneZeroEightMember_zIgpVc7dSHv6" style="text-align: right" title="Options outstanding">21,000</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneZeroEightMember_zv0CGBefPTj2" title="Expiry date">February 27, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineEightFourMember_zIXChlB4YcFg" title="Exercise price">0.0984</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineEightFourMember_zYYv6QNA18V2" style="text-align: right" title="Options outstanding">180,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineEightFourMember_zWheakZZk4A1" style="text-align: right" title="Options outstanding">180,100</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineEightFourMember_zjWXWsZNh0H3" title="Expiry date">August 2, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroSevenTwoNineMember_zWDjCkVGSnE6" title="Exercise price">0.0729</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroSevenTwoNineMember_z18d2sVSypaa" style="text-align: right" title="Options outstanding">31,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroSevenTwoNineMember_zJptTp47PGLe" style="text-align: right" title="Options exercisable">31,000</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroSevenTwoNineMember_zjoC53LHIXVa" title="Expiry date">May 20, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixTwoMember_zzbEhf9h2tb4" title="Exercise price">0.1162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixTwoMember_zGDop575mrKh" style="text-align: right" title="Options outstanding">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixTwoMember_zfVKMSf8thV5" style="text-align: right" title="Options exercisable">150,000</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixTwoMember_zLIsXeVhrgv" title="Expiry date">February 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneThreeOneZeroMember_zWGxhZw1Gsha" title="Exercise price">0.1310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneThreeOneZeroMember_zZUxczdTC921" style="text-align: right" title="Options outstanding">474,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneThreeOneZeroMember_zOcOYyDhID8h" style="text-align: right" title="Options exercisable">474,700</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneThreeOneZeroMember_znmpABlBy3Uc" title="Expiry date">January 13, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixFiveMember_z4VbKUtSCqO7" title="Exercise price">0.1165</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixFiveMember_zdnd36DJvxud" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">12,600</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixFiveMember_zkLY2SZI6LY8" style="border-bottom: Black 1pt solid; text-align: right" title="Options exercisable">12,600</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixFiveMember_zODDyhnTkr8l" title="Expiry date">November 1, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember_zxwsqR8TqV77" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">1,269,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember_zxSIxXQp7Lpd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable">1,269,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">f.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Restricted Share Units</td></tr> </table> <p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zEnQfAPcDws8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the number of RSU’s granted to directors under the Omnibus Plan for nine-month period ended April 30, 2026: SCHEDULE OF RESTRICTED STOCK UNITS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RSU’s</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Balance, July 31, 2025</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZ89yT5H9ECa" style="font-weight: bold; text-align: right" title="Number of RSU's outstanding, beginning balance">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zygXHrY0BRHj" style="font-weight: bold; text-align: right" title="Aggregate intrinsic value, beginning balance">-</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Granted (i)</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKGkp_zvY5xohoMLfd" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Number of RSU's outstanding, granted">40,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingGranted_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKGkp_zeSizZkneyFi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Aggregate intrinsic value, granted">376,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Balance, April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zv0CgDbtf68" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of RSU's outstanding, ending balance">40,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7A5gMaXuOjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Aggregate intrinsic value, ending balance">167,200</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif">On September 24, 2025, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFU1RSSUNURUQgU1RPQ0sgVU5JVFMgR1JBTlRFRCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250924__20250924__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zPIknrebJRv5" title="RSU's, granted">40,000 RSUs to directors under the Omnibus Plan. These RSUs vest in full on the earlier of September 23, 2028 or the occurrence of a change of control, resignation, or dismissal without cause. The grant-date fair value of these RSUs was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFU1RSSUNURUQgU1RPQ0sgVU5JVFMgR1JBTlRFRCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20250924__20250924__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrcezrmoeu4g" title="Number of options granted">376,000.</td></tr> </table> <p id="xdx_899_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zWG8M4iEwhKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the number of BriaPro RSU’s granted to directors under the Omnibus Plan for the nine-month period ended April 30, 2026: SCHEDULE OF BRIAPRO RESTRICTED STOCK UNITS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RSU’s</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; text-align: justify">Balance, July 31, 2025</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_zJgkSsy0s8m5" style="width: 16%; font-weight: bold; text-align: right" title="Number of RSU's outstanding, beginning balance">19,200</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_z6XvSFBeSr28" style="width: 16%; font-weight: bold; text-align: right" title="Aggregate intrinsic value, beginning balance">700</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted (i)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_fKGkp_zxDWiawWOyvd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSU's outstanding, granted">7,189,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingGranted_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_fKGkp_zqP2euampW03" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, granted">262,399</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Balance, April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_zgXiuoKYuZka" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of RSU's outstanding, ending balance">7,208,200</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_zhiXB8Qe2x36" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Aggregate intrinsic value, ending balance">263,099</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif">On April 1, 2026, BriaPro granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJSSUFQUk8gUkVTVFJJQ1RFRCBTVE9DSyBVTklUUyBHUkFOVEVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260401__20260401__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zGrotFDwU1vi" title="RSU's, granted">7,189,000 RSUs to directors under the Omnibus Plan. These RSUs vest in full on April 1, 2027. The grant-date fair value of these RSUs was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJSSUFQUk8gUkVTVFJJQ1RFRCBTVE9DSyBVTklUUyBHUkFOVEVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20260401__20260401__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_z1XKxpqIVfbb" title="Number of options granted">262,399, based on a grant-date fair value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJSSUFQUk8gUkVTVFJJQ1RFRCBTVE9DSyBVTklUUyBHUkFOVEVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20260401__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_zHt5vGjLszhi" title="Grant-date fair value">0.0365 per RSU.</td></tr> </table> BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 7: SHARE-BASED COMPENSATION (Cont.) g. Performance Share Units <p id="xdx_899_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zItTzg1dsBG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the number of PSU’s granted under the Omnibus Plan for nine-month period ended April 30, 2026: SCHEDULE OF PERFORMANCE SHARE UNITS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">PSU’s</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Balance, July 31, 2025</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zYJGpSOk8F6a" style="font-weight: bold; text-align: right" title="Number of PSU's outstanding, beginning balance">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zT3NnaIDH7uf" style="font-weight: bold; text-align: right" title="Aggregate intrinsic value, beginning balance">-</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Granted (i)</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKGkp_zsBEpjzVkXb6" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Number of PSU's outstanding, granted">165,935</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingGranted_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKGkp_z9WF0Mat2ML4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Aggregate intrinsic value, granted">1,434,513</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Balance, April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztG2n8EMXJNi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of PSU's outstanding, ending balance">165,935</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zmfK8xlLBGpa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Aggregate intrinsic value, ending balance">693,608</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif">On August 1, 2025, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250801__20250801__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQzo4ijcu3c1" title="Number of PSU's outstanding, granted">65,935 performance-based stock units (“PSUs”) to the Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”), Chief Medical Officer (“CMO”), and Chief Scientific Officer (“CSO”) under the Omnibus Plan. These PSUs contain performance conditions tied to the advancement of the Company’s Bria-IMT Phase 3 program, the Bria-OTS program, and certain corporate and governance objectives. The grant-date fair value of the PSUs awarded to these officers totaled $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250801__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zYty9ExhJyO" title="Grant date fair value">353,228. The PSUs awarded to the CMO and CSO include milestones related to the Bria-OTS program, with grant-date fair values of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250801__us-gaap--AwardTypeAxis__srt--OfficerMember_zOhdZzHCyngj" title="Grant date fair value">70,643 each. The CFO’s PSUs relate to corporate and financial reporting objectives, with a grant-date fair value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250801__us-gaap--AwardTypeAxis__srt--ChiefFinancialOfficerMember_zajLDvHCbr51" title="Grant date fair value">70,643. On September 24, 2025, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250924__20250924__srt--TitleOfIndividualAxis__srt--DirectorMember_zxwvUe6PGNX2" title="Granted shares">100,000 PSUs to a director under the Omnibus Plan. These PSUs contain performance conditions related to the Company’s corporate, strategic, and governance objectives. The grant-date fair value of this award was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250924__srt--TitleOfIndividualAxis__srt--DirectorMember_z45G6DRiWzoi" title="Grant date fair value">940,000, determined using the closing price of the Company’s common stock on the grant date. The fair value of all PSU awards was determined using the closing price of the Company’s common stock on the respective grant dates. In accordance with ASC 718, management evaluates the probability of achieving each performance condition at each reporting date. As of April 30, 2026, management has determined that achievement of the applicable performance conditions remains probable. Compensation cost is recognized over the requisite service period on a graded vesting (tranche-by-tranche) basis. During the nine-month period ended April 30, 2026, the Company achieved the performance condition related to the CFO’s PSU’s. As a result <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zC1hoBX5RGZ7" title="Number of PSU's vested">3,532 PSUs granted to the CFO vested and became issuable during the period.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">h.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the three and nine-month period ended April 30, 2026 and 2025 is comprised as follows:</td></tr> </table> SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260201__20260430_zn2hnQl1iUz7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250201__20250430_zhXtXhi32sm2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250801__20260430_zQKpydO04vd5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240801__20250430_zGw2onaiqFA6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended April 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended April 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--ResearchDevelopmentAndClinicalTrialExpensesIncludingShareBasedCompensation_maEBASBzlcX_zNjFW8YVhcDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Research, development, and clinical trial expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">175,999</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">36,493</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">338,446</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">120,050</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--GeneralAndAdministrativeExpensesIncludingShareBasedCompensation_maEBASBzlcX_zlqg4xN63FZ" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">256,208</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">188,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">674,303</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">656,829</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_iT_mtEBASBzlcX_zQMjRaGG921h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total share-based compensation</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">432,207</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">224,815</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,012,749</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">776,879</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table>

0.15

SUMMARY OF NUMBER OF OPTIONS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average remaining contractual term (in years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Balance as of July 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zm78q6AbN1Ra" style="width: 10%; text-align: right" title="Number of options, beginning balance">13,251</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zJYbEEO80Vm4" style="width: 10%; text-align: right" title="Weighted average exercise price, beginning balance">896.61</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240801__20250731__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zdpRuiJ5FjB7" title="Weighted average remaining contractual term (in years)">1.62</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zkuG9oDdQNj5" style="width: 10%; text-align: right" title="Aggregate intrinsic value, beginning balance"> -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted (i)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_fKGkp_zGpX8P5cznm" style="text-align: right" title="Number of options, granted">328,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_fKGkp_zMlbFlZHC4a8" style="text-align: right" title="Weighted average exercise price, granted">6.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualGranted_dtY_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_fKGkp_zNpLdF0SMdKc" title="Weighted average remaining contractual term (in years), granted">4.70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantedIntrinsicValue_pp0p0_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_fKGkp_zHsCIBdkHOHe" style="text-align: right" title="Aggregate intrinsic value, granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z9luHS1txDHi" style="text-align: right" title="Number of options, expired">(4,477</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zEV4lfsS8L3j" style="text-align: right" title="Weighted average exercise price, expired">636</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zfVnzmHTnQNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, ending balance">337,474</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zGBN4DaNUQIc" title="Weighted average exercise price, ending balance">33.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z31naSJP2EI3" title="Weighted average remaining contractual term (in years)">4.61</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z6ZBVd8dCU18" title="Aggregate intrinsic value, ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable as of April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z4edOvygFnle" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable">22,912</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zN9aJXxYXxWe" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, exercisable">403.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zcteMN5qvotj" title="Weighted average remaining contractual term (in years), exercisable">3.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zsIrRPWnMldj" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, exercisable">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif">On August 1, 2025, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250801__20250801__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z1ANDJitJhS4" title="Number of options granted">37,700 stock options to employees and members of the scientific advisory board at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250801__20250801__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zwQZtCRux3Z3" title="Weighted average exercise price, granted">12.50 per share. All options vest quarterly over two years. The options expire on August 1, 2030. The grant-date fair value of the award was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20250801__20250801__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z0vN6OYmsZA4" title="Number of options issued">218,784. The fair value of options granted during the nine-month period ended April 30, 2026 was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z2QBivOFrybl" title="Expected volatility">116%, expected term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zUXv54di4mS" title="Expected term">5.0 years, risk-free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zWa6vt0zYe6a" title="Risk free interest rate">3.98%, dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250801__20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zBOhSkgQmtbd" title="Dividend yield">0%, and a stock price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260430__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zhPayC7Didf4" title="Exercise price">7.50 on the grant date. On February 1, 2026, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zXfwh9nGoE12" title="Number of options granted">291,000 stock options to employees and members of the scientific advisory board at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zYqOwhR6yYB1" title="Weighted average exercise price, granted">5.59 per share. All options vest in equal quarterly installments over two years, with the first vesting date on May 1, 2026. The options expire on February 1, 2031. The grant-date fair value of the award was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z8Sr4odnhQDc" title="Number of options issued">1,031,192. The fair value of options granted was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zIJo10REWhIj" title="Expected volatility">123%, expected term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zcED8kZGaL5b" title="Expected term">5.0 years, risk-free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zL7d6nlvP1ja" title="Risk free interest rate">3.79%, dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260201__20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_z7pXWnH1L504" title="Dividend yield">0%, and a stock price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5VTUJFUiBPRiBPUFRJT05TIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260201__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zGwV1CwhgzP2" title="Exercise price">4.30 on the grant date.</td></tr> </table>

13251

896.61

P1Y7M13D

328700

6.38

P4Y8M12D

4477

636

337474

33.06

P4Y7M9D

22912

403.06

P3Y1M24D

37700

12.50

218784

1.16

P5Y

0.0398

7.50

291000

5.59

1031192

1.23

P5Y

0.0379

4.30

2069605

P2Y3M

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zxJTEhUC4aqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options outstanding as of April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average remaining contractual term (years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options exercisable as of April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average remaining contractual term (years)</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_zGee3RbT6is8" title="Exercise price">5.59</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_z4XrorSXbCLl" style="width: 9%; text-align: right" title="Options outstanding">291,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_zEoa4WUtEXek" style="width: 9%; text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">4.75</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_z5ZnkT9SJBv9" style="width: 9%; text-align: right" title="Options exercisable">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_z6Rl2rbOHkH1" style="width: 9%; text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">4.75</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 35%"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFivePointFiveNineMember_zP6exv5okrdk" title="Expiry date">February 1, 2031</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_zrwUXc8Lzr9a" title="Exercise price">12.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_zmQn9hL6NoG3" style="text-align: right" title="Options outstanding">37,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_zm6ByxQk56G2" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">4.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_z76kCH6jDHu4" style="text-align: right" title="Options exercisable">14,138</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_zQooZ6CesUB7" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">4.25</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoPointFiveZeroMember_zmSHofEf0299" title="Expiry date">August 1, 2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_zqgZgeTX2whd" title="Exercise price">60.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_zfMPFQ1666c1" style="text-align: right" title="Options outstanding">333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_zqXcdCy5V33c" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">3.70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_z1ra45RHBXEd" style="text-align: right" title="Options exercisable">333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_zb9V1DqmniC3" style="text-align: right" title="Weighted average remaining contractual term (years)">3.70</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixZeroPointZeroZeroMember_zWxt0qTmvzm5" title="Expiry Date">January 16, 2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_z0l0ORWDAEz8" title="Exercise price">904.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_z68dG9RvVnwi" style="text-align: right" title="Options outstanding">2,663</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_z2F3geYPB8Fb" style="text-align: right" title="Weighted average remaining contractual term (years)">2.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_zNH3B2XZimkl" style="text-align: right" title="Options exercisable">2,663</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_z7u3xZ7MAFtk" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">2.14</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroFourPointFiveZeroMember_zJUWfnp7Laii" title="Expiry Date">June 20, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zSnaFOiv0pa4" title="Exercise price">1,074.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zfQOE9w9M8F" style="text-align: right" title="Options outstanding">136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zHJ1KnhtmAGf" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">1.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zCw3C33OzNw" style="text-align: right" title="Options exercisable">136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zRgpGAws8j73" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">1.83</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointZeroZeroMember_zKm1GWTVaxw9" title="Expiry Date">February 27, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zWNohmjTSzma" title="Exercise price">907.97</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zHSLUtNcNs78" style="text-align: right" title="Options outstanding">1,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zueqZfcdXxFh" style="text-align: right" title="Weighted average remaining contractual term (years)">1.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zMohb8ziZrR4" style="text-align: right" title="Options exercisable">1,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zuxDy41zCDg7" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">1.26</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineZeroSevenPointNineSevenMember_zzywUPIlfXpg" title="Expiry Date">August 2, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_zES6TxHpUpZh" title="Exercise price">706.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_zPfKGq84FIL" style="text-align: right" title="Options outstanding">206</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_zm4RNuaYQEwj" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">1.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_zWSBZJbQURmf" style="text-align: right" title="Options exercisable">206</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_z0x3sHESprch" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">1.06</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenZeroSixPointFiveZeroMember_zrUeO3HQsvY1" title="Expiry Date">May 20, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zrr7Fka0Y1Zj" title="Exercise price">1,126.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zA18wmi6yg9k" style="text-align: right" title="Options outstanding">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zvCGU76PzuD3" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">0.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zpRfG5t9xe5" style="text-align: right" title="Options exercisable">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zpIQESDlRjwh" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">0.79</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneOneTwoSixPointFiveZeroMember_zXmKdUIne0r8" title="Expiry Date">February 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_z03Mzp6rofd9" title="Exercise price">1,270.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_z4Bj8Z7tA86f" style="text-align: right" title="Options outstanding">3,160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_zI6RnvNSrfx5" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">0.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_z2Qw7XiZmxta" style="text-align: right" title="Options exercisable">3,160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_zL8HUdmbqlKc" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">0.75</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneTwoSevenZeroPointFiveZeroMember_zEBKdqbBWMVi" title="Expiry Date">January 13, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_zkSNvDpmqe81" title="Exercise price">1,074.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_zzf8HwbBsmb7" style="text-align: right" title="Options outstanding">81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_zMWg0ENmhpJ3" style="text-align: right" title="Weighted average remaining contractual term (years), options, outstanding">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_zc80oA1eskka" style="text-align: right" title="Options exercisable">81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_zSNcbT4HTb0f" style="text-align: right" title="Weighted average remaining contractual term (years), options, exercisable">0.50</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250801__20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneZeroSevenFourPointEightThreeMember_z5WG16Ws4Wzh" title="Expiry date">November 1, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430_zJisZj3amdJ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">337,474</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430_zgkT0Izi3twe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable">22,912</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

5.59

291000

P4Y9M

2031-02-01

12.50

37700

P4Y3M

14138

P4Y3M

2030-08-01

60.00

333

P3Y8M12D

333

P3Y8M12D

2030-01-16

904.50

2663

P2Y1M20D

2663

P2Y1M20D

2028-06-20

1074.00

136

P1Y9M29D

136

P1Y9M29D

2028-02-27

907.97

1195

P1Y3M3D

1195

P1Y3M3D

2027-08-02

706.50

206

P1Y21D

206

P1Y21D

2027-05-20

1126.50

1000

P0Y9M14D

1000

P0Y9M14D

2027-02-16

1270.50

3160

P0Y9M

3160

P0Y9M

2027-01-13

1074.83

P0Y6M

2026-11-01

337474

22912

1269400

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BriaProTherapeuticsCorpMember_zkOd7sUU91ll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options outstanding as of April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options exercisable as of April 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiry Date</td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineThreeThreeMember_z2CaVp9e3rW2" title="Exercise price">0.0933</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineThreeThreeMember_zN3IWWqDH12h" style="width: 16%; text-align: right" title="Options outstanding">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineThreeThreeMember_z8nTewuNzqQ9" style="width: 16%; text-align: right" title="Options outstanding">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 40%"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineThreeThreeMember_z2iKDFRjZ8rk" title="Expiry date">June 20, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneZeroEightMember_zn4vnIUJEhoc" title="Exercise price">0.1108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneZeroEightMember_z41XXJzktckd" style="text-align: right" title="Options outstanding">21,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneZeroEightMember_zIgpVc7dSHv6" style="text-align: right" title="Options outstanding">21,000</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneZeroEightMember_zv0CGBefPTj2" title="Expiry date">February 27, 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineEightFourMember_zIXChlB4YcFg" title="Exercise price">0.0984</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineEightFourMember_zYYv6QNA18V2" style="text-align: right" title="Options outstanding">180,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineEightFourMember_zWheakZZk4A1" style="text-align: right" title="Options outstanding">180,100</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroNineEightFourMember_zjWXWsZNh0H3" title="Expiry date">August 2, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroSevenTwoNineMember_zWDjCkVGSnE6" title="Exercise price">0.0729</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroSevenTwoNineMember_z18d2sVSypaa" style="text-align: right" title="Options outstanding">31,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroSevenTwoNineMember_zJptTp47PGLe" style="text-align: right" title="Options exercisable">31,000</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointZeroSevenTwoNineMember_zjoC53LHIXVa" title="Expiry date">May 20, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixTwoMember_zzbEhf9h2tb4" title="Exercise price">0.1162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixTwoMember_zGDop575mrKh" style="text-align: right" title="Options outstanding">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixTwoMember_zfVKMSf8thV5" style="text-align: right" title="Options exercisable">150,000</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixTwoMember_zLIsXeVhrgv" title="Expiry date">February 16, 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneThreeOneZeroMember_zWGxhZw1Gsha" title="Exercise price">0.1310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneThreeOneZeroMember_zZUxczdTC921" style="text-align: right" title="Options outstanding">474,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneThreeOneZeroMember_zOcOYyDhID8h" style="text-align: right" title="Options exercisable">474,700</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneThreeOneZeroMember_znmpABlBy3Uc" title="Expiry date">January 13, 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixFiveMember_z4VbKUtSCqO7" title="Exercise price">0.1165</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixFiveMember_zdnd36DJvxud" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">12,600</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixFiveMember_zkLY2SZI6LY8" style="border-bottom: Black 1pt solid; text-align: right" title="Options exercisable">12,600</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20250801__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceZeroPointOneOneSixFiveMember_zODDyhnTkr8l" title="Expiry date">November 1, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember_zxwsqR8TqV77" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">1,269,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--BriaProOptionsMember_zxSIxXQp7Lpd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable">1,269,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

0.0933

400000

2028-06-20

0.1108

21000

2028-02-27

0.0984

180100

2027-08-02

0.0729

31000

2027-05-20

0.1162

150000

2027-02-16

0.1310

474700

2027-01-13

0.1165

12600

2026-11-01

1269400

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zEnQfAPcDws8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the number of RSU’s granted to directors under the Omnibus Plan for nine-month period ended April 30, 2026: SCHEDULE OF RESTRICTED STOCK UNITS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RSU’s</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Balance, July 31, 2025</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZ89yT5H9ECa" style="font-weight: bold; text-align: right" title="Number of RSU's outstanding, beginning balance">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zygXHrY0BRHj" style="font-weight: bold; text-align: right" title="Aggregate intrinsic value, beginning balance">-</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Granted (i)</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKGkp_zvY5xohoMLfd" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Number of RSU's outstanding, granted">40,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingGranted_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKGkp_zeSizZkneyFi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Aggregate intrinsic value, granted">376,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Balance, April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zv0CgDbtf68" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of RSU's outstanding, ending balance">40,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7A5gMaXuOjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Aggregate intrinsic value, ending balance">167,200</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif">On September 24, 2025, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFU1RSSUNURUQgU1RPQ0sgVU5JVFMgR1JBTlRFRCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250924__20250924__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zPIknrebJRv5" title="RSU's, granted">40,000 RSUs to directors under the Omnibus Plan. These RSUs vest in full on the earlier of September 23, 2028 or the occurrence of a change of control, resignation, or dismissal without cause. The grant-date fair value of these RSUs was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFU1RSSUNURUQgU1RPQ0sgVU5JVFMgR1JBTlRFRCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20250924__20250924__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrcezrmoeu4g" title="Number of options granted">376,000.</td></tr> </table>

40000

376000

40000

167200

40000

376000

<p id="xdx_899_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zWG8M4iEwhKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the number of BriaPro RSU’s granted to directors under the Omnibus Plan for the nine-month period ended April 30, 2026: SCHEDULE OF BRIAPRO RESTRICTED STOCK UNITS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RSU’s</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; text-align: justify">Balance, July 31, 2025</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_zJgkSsy0s8m5" style="width: 16%; font-weight: bold; text-align: right" title="Number of RSU's outstanding, beginning balance">19,200</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_z6XvSFBeSr28" style="width: 16%; font-weight: bold; text-align: right" title="Aggregate intrinsic value, beginning balance">700</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted (i)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_fKGkp_zxDWiawWOyvd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSU's outstanding, granted">7,189,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingGranted_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_fKGkp_zqP2euampW03" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, granted">262,399</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Balance, April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_zgXiuoKYuZka" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of RSU's outstanding, ending balance">7,208,200</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_zhiXB8Qe2x36" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Aggregate intrinsic value, ending balance">263,099</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif">On April 1, 2026, BriaPro granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJSSUFQUk8gUkVTVFJJQ1RFRCBTVE9DSyBVTklUUyBHUkFOVEVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260401__20260401__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zGrotFDwU1vi" title="RSU's, granted">7,189,000 RSUs to directors under the Omnibus Plan. These RSUs vest in full on April 1, 2027. The grant-date fair value of these RSUs was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJSSUFQUk8gUkVTVFJJQ1RFRCBTVE9DSyBVTklUUyBHUkFOVEVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20260401__20260401__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_z1XKxpqIVfbb" title="Number of options granted">262,399, based on a grant-date fair value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEJSSUFQUk8gUkVTVFJJQ1RFRCBTVE9DSyBVTklUUyBHUkFOVEVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20260401__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--BriaProTherapeuticsCorpMember_zHt5vGjLszhi" title="Grant-date fair value">0.0365 per RSU.</td></tr> </table>

19200

700

7189000

262399

7208200

263099

7189000

262399

0.0365

<p id="xdx_899_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zItTzg1dsBG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the number of PSU’s granted under the Omnibus Plan for nine-month period ended April 30, 2026: SCHEDULE OF PERFORMANCE SHARE UNITS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">PSU’s</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Balance, July 31, 2025</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zYJGpSOk8F6a" style="font-weight: bold; text-align: right" title="Number of PSU's outstanding, beginning balance">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zT3NnaIDH7uf" style="font-weight: bold; text-align: right" title="Aggregate intrinsic value, beginning balance">-</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Granted (i)</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKGkp_zsBEpjzVkXb6" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Number of PSU's outstanding, granted">165,935</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingGranted_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKGkp_z9WF0Mat2ML4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Aggregate intrinsic value, granted">1,434,513</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Balance, April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztG2n8EMXJNi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Number of PSU's outstanding, ending balance">165,935</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zmfK8xlLBGpa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Aggregate intrinsic value, ending balance">693,608</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif">On August 1, 2025, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250801__20250801__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQzo4ijcu3c1" title="Number of PSU's outstanding, granted">65,935 performance-based stock units (“PSUs”) to the Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”), Chief Medical Officer (“CMO”), and Chief Scientific Officer (“CSO”) under the Omnibus Plan. These PSUs contain performance conditions tied to the advancement of the Company’s Bria-IMT Phase 3 program, the Bria-OTS program, and certain corporate and governance objectives. The grant-date fair value of the PSUs awarded to these officers totaled $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250801__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zYty9ExhJyO" title="Grant date fair value">353,228. The PSUs awarded to the CMO and CSO include milestones related to the Bria-OTS program, with grant-date fair values of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250801__us-gaap--AwardTypeAxis__srt--OfficerMember_zOhdZzHCyngj" title="Grant date fair value">70,643 each. The CFO’s PSUs relate to corporate and financial reporting objectives, with a grant-date fair value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250801__us-gaap--AwardTypeAxis__srt--ChiefFinancialOfficerMember_zajLDvHCbr51" title="Grant date fair value">70,643. On September 24, 2025, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250924__20250924__srt--TitleOfIndividualAxis__srt--DirectorMember_zxwvUe6PGNX2" title="Granted shares">100,000 PSUs to a director under the Omnibus Plan. These PSUs contain performance conditions related to the Company’s corporate, strategic, and governance objectives. The grant-date fair value of this award was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250924__srt--TitleOfIndividualAxis__srt--DirectorMember_z45G6DRiWzoi" title="Grant date fair value">940,000, determined using the closing price of the Company’s common stock on the grant date. The fair value of all PSU awards was determined using the closing price of the Company’s common stock on the respective grant dates. In accordance with ASC 718, management evaluates the probability of achieving each performance condition at each reporting date. As of April 30, 2026, management has determined that achievement of the applicable performance conditions remains probable. Compensation cost is recognized over the requisite service period on a graded vesting (tranche-by-tranche) basis. During the nine-month period ended April 30, 2026, the Company achieved the performance condition related to the CFO’s PSU’s. As a result <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFBFUkZPUk1BTkNFIFNIQVJFIFVOSVRTIEdSQU5URUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20250801__20260430__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zC1hoBX5RGZ7" title="Number of PSU's vested">3,532 PSUs granted to the CFO vested and became issuable during the period.</td></tr> </table>

165935

1434513

165935

693608

65935

353228

70643

100000

940000

3532

SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260201__20260430_zn2hnQl1iUz7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250201__20250430_zhXtXhi32sm2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250801__20260430_zQKpydO04vd5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240801__20250430_zGw2onaiqFA6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended April 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended April 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--ResearchDevelopmentAndClinicalTrialExpensesIncludingShareBasedCompensation_maEBASBzlcX_zNjFW8YVhcDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Research, development, and clinical trial expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">175,999</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">36,493</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">338,446</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">120,050</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--GeneralAndAdministrativeExpensesIncludingShareBasedCompensation_maEBASBzlcX_zlqg4xN63FZ" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">256,208</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">188,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">674,303</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">656,829</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_iT_mtEBASBzlcX_zQMjRaGG921h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total share-based compensation</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">432,207</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">224,815</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,012,749</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">776,879</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> 175999 36493 338446 120050 256208 188322 674303 656829

432207

224815

1012749

776879

NOTE 8: FINANCIAL INCOME, NET SCHEDULE OF FINANCIAL INCOME, NET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260201__20260430_zOOgQ7sl1Yib" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250201__20250430_znMgdHQmz2ek" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250801__20260430_z9iPK9RGCba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240801__20250430_z96UCwc2uSug" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended April 30,</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended April 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--InvestmentIncomeInterest_maNIEz8sa_z5T53ve4kkD" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Interest income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">219,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">26,632</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">462,827</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">86,514</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InterestExpenseNonoperating_iN_di_msNIEz8sa_z3dcxWtYk269" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(29,631</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(36,979</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(29,631</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(36,979</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_maNIEz8sa_zP0lMolOBZKl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Foreign exchange gain (loss)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,619</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">585</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,991</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,775</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_iT_mtNIEz8sa_z6fq8I0jkCr9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Financial income, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">186,970</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,762</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">430,205</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69,310</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> SCHEDULE OF FINANCIAL INCOME, NET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260201__20260430_zOOgQ7sl1Yib" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250201__20250430_znMgdHQmz2ek" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250801__20260430_z9iPK9RGCba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240801__20250430_z96UCwc2uSug" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended April 30,</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended April 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--InvestmentIncomeInterest_maNIEz8sa_z5T53ve4kkD" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Interest income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">219,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">26,632</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">462,827</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">86,514</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InterestExpenseNonoperating_iN_di_msNIEz8sa_z3dcxWtYk269" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(29,631</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(36,979</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(29,631</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(36,979</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_maNIEz8sa_zP0lMolOBZKl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Foreign exchange gain (loss)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,619</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">585</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,991</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,775</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_iT_mtNIEz8sa_z6fq8I0jkCr9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Financial income, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">186,970</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,762</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">430,205</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69,310</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

219220

26632

462827

86514

29631

36979

29631

36979

-2619

585

-2991

19775

186970

-9762

430205

69310

NOTE 9: RESEARCH, DEVELOPMENT, AND CLINICAL TRIAL EXPENSES, NET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif">On August 25, 2025, the Company announced that it had been awarded a $2.0 million Small Business Innovation Research (SBIR) grant from the National Cancer Institute (“NCI”) to support the advancement of Bria-PROS+™ for the treatment of prostate cancer. The grant provides non-dilutive funding intended to support manufacturing activities and planned clinical evaluation of the program. The grant reimburses certain qualifying research and development expenditures incurred by the Company in connection with the program. In accordance with the Company’s accounting policy for government assistance, amounts received under the grant are recognized as a reduction of research and development expenses in the period in which the related costs are incurred. During the three and nine months ended April 30, 2026, the Company received $110,205 and $936,363, respectively, under the SBIR grant and recorded this amount as a reduction of research and development expenses in the condensed consolidated statements of operations. As of April 30, 2026, the Company may receive up to an additional $1.1 million under the grant, subject to the achievement of certain research objectives and compliance with the grant terms.</td></tr> </table>

2000000.0

110205

936363

1100000

NOTE 10: SUBSEQUENT EVENT The Company evaluated the possibility of subsequent events existing in the Company’s unaudited condensed consolidated financial statements through June 9, 2026, the date that the condensed consolidated financial statements were available for issuance. The Company is not aware of any subsequent events which would require recognition or disclosure in the consolidated financial statements, except as follows: <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in">a.</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">On June 2, 2026, the Company closed a public offering for the purchase and sale of <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260602__20260602__us-gaap--SubsidiarySaleOfStockAxis__custom--JuneTwoThousandTwentySixOfferingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDEz5wxx7b6i" title="Purchase and sale of common shares">1,449,300 common shares of the Company for aggregate gross proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20260602__20260602__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JuneTwoThousandTwentySixOfferingMember_zR3gvN7zfmp3" title="Warrant issued">4.7 million before deducting placement agent fees and other offering expenses (the “June 2026 Offering”). Each common share was sold at a public offering price of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20260602__us-gaap--SubsidiarySaleOfStockAxis__custom--JuneTwoThousandTwentySixOfferingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx83cCcM3so1">3.25 per share. In addition, the Company issued <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260602__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqMZZmFDDffd" title="Warrant issued">72,465 agent warrants. The agent warrants are immediately exercisable for a period of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20260602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1QMxZlc7sY7" title="Warrants term">five years from the closing date at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXjpM7AIIGM9" title="Exercise price">4.06.</td></tr> </table>

1449300

4700000

3.25

72465

P5Y

4.06

false false false false Briacell Legacy Warrants – see note 1(e) and note 4(a) Briacell Legacy Warrants – see note 1(e) and note 4(a) On August 1, 2025, the Company granted 37,700 stock options to employees and members of the scientific advisory board at an exercise price of $12.50 per share. All options vest quarterly over two years. The options expire on August 1, 2030. The grant-date fair value of the award was $218,784. The fair value of options granted during the nine-month period ended April 30, 2026 was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of 116%, expected term of 5.0 years, risk-free interest rate of 3.98%, dividend yield of 0%, and a stock price of $7.50 on the grant date. On September 24, 2025, the Company granted 40,000 RSUs to directors under the Omnibus Plan. These RSUs vest in full on the earlier of September 23, 2028 or the occurrence of a change of control, resignation, or dismissal without cause. The grant-date fair value of these RSUs was $376,000. On April 1, 2026, BriaPro granted 7,189,000 RSUs to directors under the Omnibus Plan. These RSUs vest in full on April 1, 2027. The grant-date fair value of these RSUs was $262,399, based on a grant-date fair value of $0.0365 per RSU.